From owner-immunology@net.bio.net Tue Mar 01 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!gatech!newsxfer.itd.umich.edu!nntp.cs.ubc.ca!unixg.ubc.ca!lpss From: lpss@unixg.ubc.ca (Alex Chang) Newsgroups: bionet.immunology Subject: Summary of neutrophil isolation methods Date: 2 Mar 1994 16:46:48 GMT Organization: University of British Columbia, Vancouver, B.C., Canada Lines: 53 Message-ID: <2l2fto$3p5@nnrp.ucs.ubc.ca> NNTP-Posting-Host: unixg.ubc.ca Hi, Folks: Several days ago, I posted a message asking for efficient ways to isolate neutrophils from human peripheral blood, I got lots of helpful messages. I'd like to thank the people who responded to my request. Here is the summary of them. A. Ficoll/Hypaque is the fastest way to isolate PMN. There are many formulations of ficoll/hypaque, some are much faster than others. The formulation we use is homemade. It takes about one and a half hours (one hour if you hurry). Mike Herron Comment: not yet received the formulation yet. B. We have used a one step method for neutrophil isolation that works well for chemotaxis assays-Polymorphprep from Nycomed, used to be distributed by Accurate, now by Gibco/BRL. Cliff Beall Research Scientist Ohio State Biotech. Ctr. C. Have you tried the Neutrophil Isolation medium. I have been using it to separate human neutrophils for the past 4 years. It is marketed by CARDINAL ASSOCIATES (Address: Cardinal Associates, P.O. Box 5220 SANTA FE, NM 87501, Ross Robinson, 1-800-359-3249, fax 505-473-5637) This one works perfectly well. You should keep it on the bench to bring it to room temp before you start separating. It is a straight forward procedure. Padmakumar Narayanan school of vet: medicine/purdue university D. I've been using magnetic beads (from Dynal) to separate rat B spleenocytes from T spleenocytes. It is very efficient. I don't known about neutrophils. It is an expensive method for start (the magnetic separator is quit expensive comparing with the coated magnetic beads), but at the end of the day, its worthwhile. I don't have the dynal catalogue here but if you need more information, I can send to you latter. Denise M. Moreira E. You should try a discontinous PERCOLL gradient of 55%/70%. PERCOLL is available from Sigma and Pharmacia. 100% PERCOLL = stock solution of PERCOLL plus 0.9% w/v NaCl. JOACHIM -- From owner-immunology@net.bio.net Tue Mar 01 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!bcm!cs.utexas.edu!swrinde!ihnp4.ucsd.edu!library.ucla.edu!news.ucdavis.edu!othello.ucdavis.edu!szjmahr From: szjmahr@othello.ucdavis.edu () Subject: capital letters Message-ID: Sender: usenet@ucdavis.edu (News Guru) Organization: University of California, Davis X-Newsreader: TIN [version 1.2 PL2] Date: Wed, 2 Mar 1994 22:46:32 GMT Lines: 23 WHY OH WHY IS IT THAT SOME ARE SO AFFECTED BY THE USE OF ALL CAPITAL LETTERS? DO YOU FEEL AS THOUGH I AM SHOUTING AT YOU? here, i'll lower my voice a little, is this better? does this preserve the sanctity of your ears? how are your eyes? perhaps i could arrange to post this in a more agreeable color. are my sentences to long? how about the spacing? but i ask you who are affected WHAT THE HELL DOES IT MATTER? THIS IS SCIENCE, PEOPLE, DON'T WE HAVE BETTER THINGS TO WORRY ABOUT? COULDN'T WE LIMIT OURSELVES TO WORTHWHILE ENDEAVORS, MAYBE EVEN SOLVE A FEW PROBLEMS WHILE WE ARE AT IT? THIS IS A COMUNICATION NETWORK not a style conference From owner-immunology@net.bio.net Tue Mar 01 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!torn!news.ccs.queensu.ca!qucdn!forsdyke Organization: Queen's University at Kingston Date: Wed, 2 Mar 1994 14:13:06 EST From: Message-ID: <94061.141306FORSDYKE@QUCDN.QueensU.CA> Newsgroups: bionet.immunology Subject: Intracellular self/not-self discrimination Lines: 77 THE NEED FOR INTRACELLULAR SELF/NOT-SELF DISCRIMINATION The maturation of immunologically competent cells involves the deletion or inactivation of cells which react with high specificity with self antigenic determinants. Since the cells first "show their colours" by displaying antigen-specific, outward-facing, receptors at their surfaces, their "education" is regarded as part of an extracellular process of self/not-self discrimination. A cell whose receptors happen to react with some free or cell-borne self-antigenic determinant will either be deleted or inactivated. The principle of intracellular self/not-self discrimination was firmly established with the discovery of bacterial restriction/modification systems. An advantage to higher multicellular organism of having an intracellular self/not-self discrimination system became particularly apparent with the finding that peptides from both self and foreign intracellular proteins can be displayed at the cell surface in association with major histocompatibility complex (MHC) proteins; here they are recognized by immunologically competent cells of the cytotoxic T cell class. In the absence of a mechanism for distinguishing intracellularly self peptides or proteins from foreign (e.g. virally-derived) peptides or proteins, cells would have to display all MHC-bound peptides. Hedrick (1992) has noted that "It is hard to understand how peptides derived from foreign antigens can compete with the tide of self peptides...", and has suggested that "Perhaps there is a mechanism that could help to sort peptides into those originating from self and those originating from foreign peptides". In the absence of such a sorting mechanism, an organism would depend solely on prior education of T cells to prevent their being activated by self-peptide-MHC complexes. Several studies indicate that this deletion of potential self-reacting T cells would create numerous gaps in the T cell repertoire, which might adversely affect resistance to infection For example, Du Pasquier and coworkers (1977) presented evidence that polyploid toad species, while apparently functionally polyploid for most genes, are functionally DIPLOID for MHC genes. That this had occurred over evolutionary time was suggested by the observation that healthy laboratory-made polyploid toads expressed all MHC loci. Since the final T cell repertoire reflects the processes of negative and positive selection, every additional functional MHC gene would increase the number of potential anti-self T cells which would have to be deleted (negative selection). This would decrease the range of foreign proteins to which the surviving positively selected cells could respond. Fitness would be impaired. Individuals which lost excess MHC loci through mutation, would then have a selective advantage so that the modern polyploid survivors would be MHC diploid. As Vidovic and Matzinger (1988) succinctly state: "There will be a selective pressure against the expression of too many MHC genes. Because the number of cells in the immune system is finite, the elimination of cells recognizing self obviously reduces the recognition repertoire of the individual." The prior sorting of peptides intracellularly would mean that populations of T cells would exist with the potential to respond against self-peptides should they be inadvertantly, or artificially, presented. Thus, Schild and coworkers (1990) found that cytotoxic T lymphocytes "are only tolerant of those endogenous self peptide sequences that are presented by MHC Class I-positive cells in a physiological manner". For a possible mechanism of intracellular self/not self discrimination see Forsdyke, 1994. REFS: Du Pasquier et al. (1977) Immunogenetics 5, 129-147. The genetic control of histocompatibility reactions in natural and laboratory-made polyploid individuals of the clawed toad Xenopus. Forsdyke, D. R. (1994) J. Biol. Systems (in press) Entropy-driven protein self-aggregation as the basis for self/not-self discrimination in the crowded cytosol. Hedrick, S. M. (1992) Cell 70, 177-180. Dawn of the hunt for non-classical MHC function. Schild et al. (1990) Science 247, 1587-89. Limit of T cell tolerance to self proteins by peptide presentation. Vidovik, D. & Matzinger, P. (1988) Nature 336, 22-225. Unresponsiveness to a foreign antigen can be caused by self-tolerance. Sincerely, Don Forsdyke, Discussion Leader, Bionet Immunology From owner-immunology@net.bio.net Wed Mar 02 22:00:00 1994 Path: biosci!daresbury!bioftp.unibas.ch!rc1.vub.ac.be!is3e!philstas From: philstas@vub.ac.be (Stas Philippe) Newsgroups: bionet.immunology Subject: Re: Immunodeficient kids needed! Date: 3 Mar 1994 11:53:22 GMT Organization: Brussels Free Universities (VUB/ULB), Belgium Lines: 21 Message-ID: <2l4j3i$5ba@rc1.vub.ac.be> References: <2l3l1i$mlp@csi0.csi.UOttawa.CA> NNTP-Posting-Host: is3e.vub.ac.be X-Newsreader: TIN [version 1.2 PL2] david creery (grad student) (g554061@labsun1.med.uottawa.ca) wrote: : I am a Pediatric resident working on a PhD in Ottawa. We don't have very : many immunodeficient children in the area. If anyone knows of a : collection of children with an immunodeficiency syndrome (e.g. : Wiskott-Aldrich, Chronic Granulomatous Disease, Chediak-Higashi, SCID : etc.) I would like to hear about it. We are trying to reconstitute the : immune system using IL-12, and I would like to try it one some cell : samples from these kids. : Thanks. : David Creery : aq045@FreeNet.Carleton.ca OR : g554061@labsun1.med.uottawa.ca Hi, Is this some kind of a joke? How can one reconstitute a immune system using IL12? Wath kind of cell sample this person wants? johor From owner-immunology@net.bio.net Wed Mar 02 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!uknet!demon!gnome.demon.co.uk!na From: na@gnome.co.uk (Nigel Appleton) Subject: IL 1 beta convertase Message-ID: Organization: Gnome Computers Ltd X-Newsreader: TIN [version 1.2 PL2] Date: Thu, 3 Mar 1994 17:01:13 GMT Lines: 9 I'm posting this for a friend who needs a source of 100 micrograms of interleukin 1 beta convertase. I should be grareful for any help - please email replies to na@gnome.co.uk -- ------------------------------------------------------------------------------ Nigel Appleton na@gnome.co.uk Practical Diagnostics Tel/Fax: 44 (0)480 471743 25A Huntingdon St, St Neots, Cambridgeshire, PE19 1BG From owner-immunology@net.bio.net Wed Mar 02 22:00:00 1994 Path: biosci!MED.PITT.EDU!bsh From: bsh@MED.PITT.EDU (Basavaraju Shankarappa) Newsgroups: bionet.immunology Subject: Re: capital letters Date: 3 Mar 1994 00:31:37 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 17 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9403030032.AA23212@mercury.med.pitt.edu> References: NNTP-Posting-Host: net.bio.net > WHY OH WHY IS IT THAT SOME ARE SO AFFECTED BY THE USE OF ALL > CAPITAL LETTERS? DO YOU FEEL AS THOUGH I AM SHOUTING AT YOU? > WHAT THE HELL DOES IT MATTER? THIS IS SCIENCE, PEOPLE, DON'T WE > HAVE BETTER THINGS TO WORRY ABOUT? COULDN'T WE LIMIT OURSELVES TO > WORTHWHILE ENDEAVORS, MAYBE EVEN SOLVE A FEW PROBLEMS WHILE WE ARE AT IT? > > THIS IS A COMUNICATION NETWORK > May be for all those who insist on (intentionally or otherwise) typing with all UPPERCASE, may be if you type with two line spacing will make it easy on others to read. Raj. From owner-immunology@net.bio.net Wed Mar 02 22:00:00 1994 Path: biosci!bloom-beacon.mit.edu!gatech!howland.reston.ans.net!torn!nott!uotcsi2!labsun1.med.uottawa.ca!g554061 From: g554061@labsun1.med.uottawa.ca (david creery (grad student)) Newsgroups: bionet.immunology Subject: Immunodeficient kids needed! Date: 3 Mar 1994 03:20:18 GMT Organization: Department of Computer Science, University of Ottawa Lines: 14 Message-ID: <2l3l1i$mlp@csi0.csi.UOttawa.CA> NNTP-Posting-Host: labsun1.med.uottawa.ca X-Newsreader: TIN [version 1.1 PL8] I am a Pediatric resident working on a PhD in Ottawa. We don't have very many immunodeficient children in the area. If anyone knows of a collection of children with an immunodeficiency syndrome (e.g. Wiskott-Aldrich, Chronic Granulomatous Disease, Chediak-Higashi, SCID etc.) I would like to hear about it. We are trying to reconstitute the immune system using IL-12, and I would like to try it one some cell samples from these kids. Thanks. David Creery aq045@FreeNet.Carleton.ca OR g554061@labsun1.med.uottawa.ca From owner-immunology@net.bio.net Wed Mar 02 22:00:00 1994 Path: biosci!SPEEDY.COACADE.UV.MX!evargas From: evargas@SPEEDY.COACADE.UV.MX (Enrique Vargas) Newsgroups: bionet.immunology Subject: Phone number Date: 3 Mar 1994 01:09:25 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 14 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9403030114.AA01677@speedy.speedy.coacade.uv.mx> NNTP-Posting-Host: net.bio.net Hi! I want to know if somebody can send me the Tai Te Wu, George Johnson or the Kabat database administrators phone number for ask them: When this database is available again by INTERNET? Thanks in advance. ******************************************************************************* * Enrique Vargas-Madrazo * evargas@speedy.coacade.uv.mx * ******************************************************************************* * Laboratorio de Biologia Molecular * Phone number: (28)125757 * * e Inmunologia Teorica. * FAX number: (28)125757 * ******************************************************************************* * Instituto de Investigaciones Biologicas * Universidad Veracruzana * * * Xalapa, Veracruz; Mexico. * ******************************************************************************* From owner-immunology@net.bio.net Wed Mar 02 22:00:00 1994 Path: biosci!MUSIC.FERRIS.EDU!MRYAN From: MRYAN@MUSIC.FERRIS.EDU ("Ryan, Michael") Newsgroups: bionet.immunology Subject: AZT use during pregnancy Date: 3 Mar 1994 18:40:22 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 3 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <03MAR94.14697000.0215.MUSIC@MUSIC.FERRIS.EDU> NNTP-Posting-Host: net.bio.net I'm looking for the journal citation to support the 7march1994 Newsweek article entitled "Locking HIV Out of the Womb" by G.Cowley. If you know, please "zip me a line"! Thanks in advance. From owner-immunology@net.bio.net Thu Mar 03 22:00:00 1994 Path: biosci!UABCVSR.CVSR.UAB.EDU!txpljfg From: txpljfg@UABCVSR.CVSR.UAB.EDU Newsgroups: bionet.immunology Subject: Re: stress hormones and opoptosis Date: 4 Mar 1994 22:46:32 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 32 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <940304164910.35163@UABCVSR.cvsr.uab.edu> References: <1994Mar4.211055.22519@blaze.trentu.ca> NNTP-Posting-Host: net.bio.net One person who was looking at glucocorticoids and apoptosis a while back (I don't know if he is still interested in this area) is J. John Cohen at the University of Colorado Health Sciences Center. You might try looking up his references to see if there is any thing recent. good luck > My first posting to this news group!!! > > It was great to finally find this medium to expound on ideas in > this exciting field. My research for my academic endeavors focuses within > the field of psychoneuroimmunology (PNI). I have a particular interest in > glucocorticoids and their influence on opoptosis. I am however, getting > bottlenecked for information on programmed cell destruction. Any offered > information in this area would be greatly appreciated. > > **************************************************************************** > It is not the goal itself that holds to ultimate > satisfaction. The effort qualifies the outcome!! > **************************************************************************** > CWHALE@TRENTU.ON.CA > > ============================================================================== James F. George, Ph.D. "Back off man, I'm a scientist" Department of Surgery --Bill Murray University of Alabama at Birmingham 205-934-4261 voice txpljfg@uabcvsr.cvsr.uab.edu =============================================================================== From owner-immunology@net.bio.net Thu Mar 03 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!daresbury!trane.uninett.no!sunic!pipex!howland.reston.ans.net!torn!blaze.trentu.ca!TrentU.CA!CWHALE From: cwhale@TrentU.CA (chris whale) Subject: stress hormones and opoptosis Message-ID: <1994Mar4.211055.22519@blaze.trentu.ca> Sender: news@blaze.trentu.ca (USENET News System) Reply-To: cwhale@TrentU.CA Organization: Trent University, Peterborough Date: Fri, 4 Mar 1994 21:10:55 GMT Lines: 15 My first posting to this news group!!! It was great to finally find this medium to expound on ideas in this exciting field. My research for my academic endeavors focuses within the field of psychoneuroimmunology (PNI). I have a particular interest in glucocorticoids and their influence on opoptosis. I am however, getting bottlenecked for information on programmed cell destruction. Any offered information in this area would be greatly appreciated. **************************************************************************** It is not the goal itself that holds to ultimate satisfaction. The effort qualifies the outcome!! **************************************************************************** CWHALE@TRENTU.ON.CA From owner-immunology@net.bio.net Thu Mar 03 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!usc!yeshua.marcam.com!zip.eecs.umich.edu!panix!ddsw1!news.cic.net!magnus.acs.ohio-state.edu!lritter From: lritter@magnus.acs.ohio-state.edu (Linda M Ritter) Newsgroups: bionet.immunology Subject: Need Help Culturing U937 cells Date: 4 Mar 1994 15:46:36 GMT Organization: The Ohio State University Lines: 20 Sender: lritter@magnus.ohio-state.edu Message-ID: <2l7l4s$orm@charm.magnus.acs.ohio-state.edu> NNTP-Posting-Host: top.magnus.acs.ohio-state.edu Summary: Tissue culture advice needed To anyone who can help me: I am a graduate student at the Ohio State University in the Molecular Genetics department. I have had this problem before and have just come up against it again today. If anyone could help me it would be greatly appreciated. When I grow my U937 cells in RPMI with 10% FBS in flasks the grow exceptionally well and expand quickly. They all look healthy and the culture is uniform. However, when I then transfer them to spinner flasks, their growth slows almost to a stand-still and the culture does not look as uniform as it had. I gas the flasks when I transfer the cells. The cultures are not contaminated. I don't know what causes this. If anyone could help, please either e-mail me at lritter@magnus.ohio-state.edu or post a reply to this usernet. Thank you for your help. Linda From owner-immunology@net.bio.net Thu Mar 03 22:00:00 1994 Path: biosci!daresbury!not-for-mail From: PAPAGEORGIOU GEORGIOS Newsgroups: bionet.immunology Subject: INVITATION TO GREEK BIOSCIENTISTS Date: 4 Mar 1994 06:16:26 -0000 Lines: 45 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2l6jnq$9mu@mserv1.dl.ac.uk> X-Char-Esc: 29 X-Charset: ELOT_928 Original-To: immuno@dl.ac.uk * * * * INVITATION TO GREEK BIOLOGICAL SCIENTISTS * * * * The Institute of Biology of the National Research Center Demokritos in Athens, Greece, is interested in compiling a list of Greek research scientists working in diverse fields of life sciences who might be interested in future staff openings at the Institute. The information will be used to formulate the expansion policy of the Institute. Please send brief memo including name, addresses (postal mail, e-mail, telefax, telephone), present affiliation and research area. A list of publications will be helpful. A rough sketch of research areas in the Institute of Biology includes, but it is not limited to, the following: BASIC BIOSCIENCE Mammalian gene expression; cytokines and oncogenes; human serum growth factors; cell regulation mechanisms; opioid peptides and receptors; transmembrane signals; lectines; photosynthesis (function, regulation, biogenesis); developmental theoretical biology. APPLIED BIOSCIENCE Environmental genotoxicity; radiation induced mutations; primary sea productivity and phytoplanckton; chemical communication of insects (feromones); management of insect populations; insect ecophysiology; insect nutrition; soil microbiology; uptake of radioactive nuclides by plants. Please disseminate this information to other interested scientists you may know. Thank you. Contact person: Dr. George C. Papageorgiou, Director NRC Demokritos, Institute of Biology Athens, Greece 153 10 _______________________________ Telefax : (301) 651 1767 Telephone : (301) 652 2018 E-mail: gcpap@cyclades.nrcps.ariadne-t.gr _______________________________  From owner-immunology@net.bio.net Thu Mar 03 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!gatech!newsxfer.itd.umich.edu!news.cic.net!magnus.acs.ohio-state.edu!lritter From: lritter@magnus.acs.ohio-state.edu (Linda M Ritter) Newsgroups: bionet.immunology Subject: Help needed with U937 cells Date: 4 Mar 1994 17:19:30 GMT Organization: The Ohio State University Lines: 8 Sender: lritter@magnus.acs.ohio-state.edu Message-ID: <2l7qj2$p8h@charm.magnus.acs.ohio-state.edu> NNTP-Posting-Host: top.magnus.acs.ohio-state.edu Summary: Wrong e-mail address given I omitted part of my e-mail address. The correct address is lritter@magnus.acs.ohio-state.edu Thank you for the help in answering my question. Linda From owner-immunology@net.bio.net Thu Mar 03 22:00:00 1994 Path: biosci!headwall.Stanford.EDU!ladasky From: ladasky@leland.Stanford.EDU (John Ladasky) Newsgroups: bionet.immunology Subject: Re: Capital Letters Date: 4 Mar 1994 01:47:18 GMT Organization: Stanford University, CA 94305, USA Lines: 50 Message-ID: <2l63v6$ekr@nntp2.Stanford.EDU> References: NNTP-Posting-Host: elaine44.stanford.edu I didn't read the original objection to all-caps postings, so I don't know whether the objection was a friendly one. But this recent posting is clearly not friendly. If a flamewar ensues (in a bionet newsgroup?), please, let's all be ready to take it to alt.flame. In article , wrote (and I have gratuitously edited his writing): > WHY OH WHY IS IT THAT SOME ARE SO AFFECTED BY THE USE OF ALL >CAPITAL LETTERS? DO YOU FEEL AS THOUGH I AM SHOUTING AT YOU? > > how are your eyes? This is actually a relevant point. My eyes find it much easier to read sentences which include lower case letters. I think this is true for a lot of people... how about you? > WHAT THE HELL DOES IT MATTER? THIS IS SCIENCE, PEOPLE, DON'T WE >HAVE BETTER THINGS TO WORRY ABOUT? COULDN'T WE LIMIT OURSELVES TO >WORTHWHILE ENDEAVORS, MAYBE EVEN SOLVE A FEW PROBLEMS WHILE WE ARE AT IT? > > THIS IS A COMUNICATION NETWORK > > not a style conference Speaking for myself, I'd *prefer* it if I could get at the essence of something without being sidetracked by the manner of presentation. And frequently I can do so where others cannot. I have been known to argue rather strenously with relatives and colleagues who believe in "dressing well." But unfortunately for all of us, even us relatively non-conformist, high-brain-plasticity science types, style impacts communication. The par- ticular style that we prefer may merely be the product of repeated exposure (I'm not sure there's anything inherent about all-caps being less readable), but there's no doubt that style impacts people's ability (or willingness) to listen/read/whatever. And as the poster from Davis said, this *is* a communication network. I wouldn't consider it impolite to ask someone to try to make it easier for me to understand their writing. It will make it easier to focus on those "worthwhile endeavors" and to "solve a few problems." Just another radical Berkeley undergrad who somehow wound up at Stanford, - John Ladasky From owner-immunology@net.bio.net Fri Mar 04 22:00:00 1994 Path: biosci!WRAIR-EMH1.ARMY.MIL!dexper From: dexper@WRAIR-EMH1.ARMY.MIL Newsgroups: bionet.immunology Subject: re: stress hormones and apoptosis Date: 5 Mar 1994 03:09:46 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 11 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403050309.TAA00735@net.bio.net> NNTP-Posting-Host: net.bio.net J. John Cohen has a review of programmed cell death in Advances in Immu- nology vol. 50 p. 55-85, 1991. Other reviews include: Arends, M.J. and Wyllie, A.H., Int. Rev. Exp. Pathol. 32:223 (1991), Marrack et al., Immunol. Rev. 133:119 (1993), Cohen, J.J., Hospital Practice Dec. 15, 1993 p. 35, Martin, S.J. et al., Trends in Biochemical Sci. 19:26, 1994, Taylor, R., J. NIH Research 5:59 (1993). There are two articles in the 20 Jan 1994 Nature on the role of the orphan steroid hormone receptor Nur77 in apoptosis of T cells. Jack Komisar Dexper@Wrair-emh1.army.mil From owner-immunology@net.bio.net Fri Mar 04 22:00:00 1994 Newsgroups: bionet.immunology From: postmaster@johnhunt.demon.co.uk (John Hunt) Path: biosci!daresbury!trane.uninett.no!sunic!pipex!uknet!demon!johnhunt.demon.co.uk!postmaster Subject: Rev Med Microbiol Organization: Wizzard Prang Software Reply-To: Postmaster@johnhunt.demon.co.uk X-Newsreader: Demon Internet Simple News v1.27 Lines: 13 Date: Sat, 5 Mar 1994 15:37:57 +0000 Message-ID: <762881877snz@johnhunt.demon.co.uk> Sender: usenet@demon.co.uk I've been given a reference: Fieldman RG, Fleer A. The Immune response of the Group B Streptococcus. Rev Med Microbiol 1992;3:488-490. Can anybody give me any information about this, such as where I can find it, and the full name of the publication? Thanking you in advance. -- postmaster@johnhunt.demon.co.uk From owner-immunology@net.bio.net Fri Mar 04 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!bcm!cs.utexas.edu!swrinde!emory!europa.eng.gtefsd.com!news.msfc.nasa.gov!cs.utk.edu!martha.utcc.utk.edu!usenet From: vrdiderr@utkvx.utk.edu Subject: RE: Invasion by unknown organism Message-ID: <1994Mar5.161643.19386@martha.utcc.utk.edu> Lines: 14 Sender: usenet@martha.utcc.utk.edu (USENET News System) Organization: University of Tennessee References: , Date: Sat, 5 Mar 1994 07:16:37 GMT In Article p92126@cplab.ph.ed.ac.uk (James Talbot) writes: >If the body developes a disease, is there anyway of identifying >the culprit responsible, without any information about >the organism. ------------------------------------------------------------------ If the host dies, a Pathologist can almost always find out via bacterial cultures, virus isolation and histopath. > > > From owner-immunology@net.bio.net Sat Mar 05 22:00:00 1994 Path: biosci!WRAIR-EMH1.ARMY.MIL!dexper From: dexper@WRAIR-EMH1.ARMY.MIL Newsgroups: bionet.immunology Subject: Rev Med Microbiol Date: 6 Mar 1994 04:09:26 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 6 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403060409.UAA00778@net.bio.net> NNTP-Posting-Host: net.bio.net The full title of this journal is Reviews in Medical Microbiology. it looks like smaller libraries don't have it. It is in the Cambridge Univer- sity library. Maybe you can get it by interlibrary loan. Jack Komisar dexper@wrair-emh1.army.mil From owner-immunology@net.bio.net Sat Mar 05 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!bcm!cs.utexas.edu!swrinde!sgiblab!nec-gw!netkeeper.sj.nec.com!vivaldi!seas.smu.edu!rgarcia From: rgarcia@sun.cis.smu.edu (Ryan Garcia) Subject: information Message-ID: <1994Mar6.003243.24251@seas.smu.edu> Originator: rgarcia@sun.cis.smu.edu Sender: news@seas.smu.edu (USENET News System) Nntp-Posting-Host: sun.cis.smu.edu Organization: Computing and Information Services Distribution: usa Date: Sun, 6 Mar 1994 00:32:43 GMT Lines: 16 I do not want to be bothersome by posting to this newsgroup several times, so I am asking that someone please give me the information that I am requesting. I need to find: 1) Archive Copy of The FAQ'S of the newsgroup 2) Charter of Newsgroup a) Statement of Purpose b) FTP Archive Site c) Significant Topics covered in the group This will save your time by not having to read anymore of my postings about such information and save my time by not having to post and ask for such information. Any help would be greatly appreciated. Thank you, Ryan From owner-immunology@net.bio.net Sat Mar 05 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!bcm!cs.utexas.edu!swrinde!sgiblab!nec-gw!netkeeper.sj.nec.com!vivaldi!seas.smu.edu!rgarcia From: rgarcia@sun.cis.smu.edu (Ryan Garcia) Subject: information Message-ID: <1994Mar6.001354.21543@seas.smu.edu> Originator: rgarcia@sun.cis.smu.edu Sender: news@seas.smu.edu (USENET News System) Nntp-Posting-Host: sun.cis.smu.edu Organization: Computing and Information Services Distribution: usa Date: Sun, 6 Mar 1994 00:13:54 GMT Lines: 16 I do not want to be bothersome by posting to this newsgroup several times, so I am asking that someone please give me the information that I am requesting. I need to find: 1) Archive Copy of The FAQ'S of the newsgroup 2) Charter of Newsgroup a) Statement of Purpose b) FTP Archive Site c) Significant Topics covered in the group This will save your time by not having to read anymore of my postings about such information and save my time by not having to post and ask for such information. Any help would be greatly appreciated. Thank you, Ryan From owner-immunology@net.bio.net Sun Mar 06 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!news.intercon.com!panix!zip.eecs.umich.edu!quip.eecs.umich.edu!schuette From: schuette@quip.eecs.umich.edu (R. Wade Schuette) Newsgroups: bionet.immunology Subject: Any evidence Communicable Immunity? Date: 7 Mar 1994 07:50:28 GMT Organization: University of Michigan EECS Dept. Lines: 40 Message-ID: <2lemc4$jmg@zip.eecs.umich.edu> NNTP-Posting-Host: quip.eecs.umich.edu X-Newsreader: TIN [version 1.2 PL0] This may be a dumb question, and I apologize if it's emotionally charged, but I'm working on a paper on adaptive systems and came across this question that I really had no idea about; After fetal development and breast-feeding, which have obvious mechanisms, is there any evidence for communication between immune systems directly of working responses against pathogens? I'm interested in plants as well as animals, and secondarily in signalling mechanisms to invoke existing responses, but primarily in solution of the problem in one immune system and transmission of that answer to other immune systems, a human counterpart of Multiple Drug Resistant exchange of attacking/defense strategies. Obviously people with labs and hypodermics can facilitate such exchanges, ala "immunizations". But what occurs "naturally"? Anecdotal information, blue-sky speculation, as welcome as peer-reviewed journal references. Theoretical arguements why this might, Must, Can't possibly occur also welcome. E-mail long stuff or flame-war bait, and I'll preprocess and post the results or summarize the structure of the thinking. Basically, one way to look at this is, besides Acquired Immune Deficits, are there Acquired Immune Strengths? -- *-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-* _u "Did you ever notice O__ That when you think about a problem at 2 AM, _LL__ And then again at noon the next day, /_____\ You get two different answers?" |_[#]_| Snoopy (Schultz) |_[#]_| ------------------------------------------------------------------------- From owner-immunology@net.bio.net Sun Mar 06 22:00:00 1994 Path: biosci!daresbury!bioftp.unibas.ch!rc1.vub.ac.be!dec5dbm.ulb.ac.be!tsornas From: tsornas@dbmdec5.ulb.ac.be (Thierry Sornasse) Newsgroups: bionet.immunology Subject: Nude mice: immune defects other than T cells ? Date: 7 Mar 1994 13:36:46 GMT Organization: Brussels Free Universities VUB/ULB Lines: 33 Sender: tsornas@dec5 (Thierry Sornasse) Distribution: world Message-ID: <2lfale$jef@rc1.vub.ac.be> NNTP-Posting-Host: dbmdec5.ulb.ac.be Hi Immunenetters, I study the possible influence of T cells on the maturation of DC. Since Nude mice have a little number of fonctionnal T cells, I work with type of mice. Although, I am wondering if the Nude mutation has other affects on other cells type of the immune system. I know that some authors suggest that B cells of Nu/Nu mice are not normal but is there any evidence for that ? I would like also to know if other cell types like monocytes/macrophages, granulocytes, NK cells, mastocytes are affected by the Nu mutation ? Thank you in advance for your help Bye ///////////////////////////////////////////////////////////////////////// / / T H I E R R Y S O R N A S S E / / Laboratoire de Physiologie Animale / / Universite Libre de Bruxelles / Free University of Brussels / Rue des Chevaux, 67. 1640 Rhode-St-Genese / B E L G I U M / / Phone: 32.2.6509850 Fax: 32.2.6509840 / tsornas@dbmdec5.ulb.ac.be / / //////////////////////////////////////\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ From owner-immunology@net.bio.net Mon Mar 07 22:00:00 1994 Path: biosci!genpharm.com!dmoregan From: dmoregan@genpharm.com ("Donna Munoz O'Regan") Newsgroups: bionet.immunology Subject: ELISA MICROPLATE WASHERS Date: 8 Mar 1994 22:11:46 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 19 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403082145.NAA27905@netcomsv.netcom.com> NNTP-Posting-Host: net.bio.net GenPharm Memoo Subject: ELISA MICROPLATE WASHERS Date: Time: 3.8.94 12:46 PM Hi, We're looking into buying an ELISA microplate washer which will wash multiple plates. They're called stackers. And I've found only a few out there, Denley, Titertek. Does anyone have one of these plate stacker washers? Do you like it? Are there any other vendors you know about and can you email their names and telephone numbers? Thanks very much. Donna. email: dmoregan@genpharm.com my opinions only, if you want one you have to get your own, or at least and pi and an onion. From owner-immunology@net.bio.net Mon Mar 07 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!daresbury!trane.uninett.no!sunic!pipex!howland.reston.ans.net!gatech!news-feed-1.peachnet.edu!umn.edu!news From: brambl@graz.cbs.umn.edu (Robert Brambl) Subject: search for cyclosporin A Message-ID: Sender: news@news.cis.umn.edu (Usenet News Administration) Nntp-Posting-Host: graz.cbs.umn.edu Reply-To: brambl@molbio.cbs.umn.edu (Robert Brambl) Organization: University of Minnesota, Twin Cities Date: Tue, 8 Mar 1994 21:19:48 GMT Lines: 12 Hello, all: We are attempting to find a source of cyclosporin A or FK506 for a study of mitochondrial membrane proteins in Neurospora. ICN sold cyclosporin until recently, but they no longer have it available. It would be helpful to receive either vendor information or the name of the manufacturer. Thanks and best wishes. Robert Brambl University of Minnesota brambl@molbio.cbs.umn.edu From owner-immunology@net.bio.net Mon Mar 07 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!europa.eng.gtefsd.com!library.ucla.edu!ihnp4.ucsd.edu!usc!cs.utexas.edu!news.tamu.edu!not-for-mail From: acc4636@tamsun.tamu.edu (Anthony C.) Newsgroups: bionet.immunology Subject: Opinions on whether TH1 and TH2 cell types originate from TH0 Date: 8 Mar 1994 14:32:52 -0600 Organization: Texas A&M University, College Station Lines: 14 Message-ID: <2lindk$1uv@tamsun.tamu.edu> NNTP-Posting-Host: tamsun.tamu.edu Hello, I am wondering what peoples opinions are on the idea that TH1 and TH2 phenotypes that are localized in an infection are a result of differentiation of the TH0 phenotype. Also, what are your feelings on a good definition of TH1 and TH2 phenotypes. While the original definition was characterized by multiple cytokines, it seems that more and more papers are focusing just on Il4 and Il-10 to demonstrate a TH2 phenotype and Il-2 and IFN-gamma to demonstrate a Th1 phenotype. Also, some labs use an Il-4/IFN-gamma ratio rather than absolute numbers as a measure of the phenotype since most cells secrete at least a little of both. There is a lot of evidence to support the TH0---> Th1/Th2 concept (but I dont have citations with me) and it seems to make sense in the same way that monocytes are present in the blood stream and localize to tissue and differentiate into macrophages. I hope that this can spark some kind of discussion to liven up the group. From owner-immunology@net.bio.net Mon Mar 07 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!pipex!zaphod.crihan.fr!news.univ-rennes1.fr!nmenoux From: nmenoux@univ-rennes1.fr (Nicolas Menoux) Newsgroups: bionet.immunology Subject: =v=v=== IMMUNOLOGY ===v=v= Date: 8 Mar 1994 15:27:16 GMT Organization: Universite de Rennes 1, France Lines: 176 Message-ID: <2li5gk$aho@news.univ-rennes1.fr> NNTP-Posting-Host: simpa3.univ-rennes1.fr X-Newsreader: TIN [version 1.2 PL1] Nicholas MENOUX 10, rue Michelet F35700 RENNES FRANCE Phone: (33)99368508 Fax: (33)99286957 Mar.7 1994 Hello ! To be honest, I must say that I am quite desperate . Why ? It is a long time I've been looking for a full time or contract positions within immunology laboratories but it still doesn't work ! It is true that I've no educational immunology background but as I am very inquiring spirit and very motivated, I've read lots of book, articles, discuss with many immunologists, that's why I can say now that I am a 'good' novice in that domain. I do not pretend to work of course as a high skilled researcher in immunology but I think that my computing background and experience could be a good contribution to many immunology research programs. I am really interested in switching in this research field, especially in TCells and MHC molecules, HIV,... I really want to work for researchers by designing and carrying out graphic tools systems with PCs or workstations like sparc, RS/6000,etc.. I am motivated to learn immunology technics and knowledge and help researchers in their works. I have a strong interest in Image (3D, 2D). I think I have a good Graphic interface background with numerous platforms like OpenLook, XWindow, MS-Windows, GKS. Moreover, my educational background in harware could be a plus to develop some new devices in order to improve Human-Machine interface in immunology like virtual realities (example: travel inside the human body and analyse, modelize Cells receptors - paratope/epitope , carry out 3D animations to improve communication impact during conferences, and so on...) As you can see, I have the research feeling and I am always fascinated in working for research. I got my Master degree in Computer Science and Electrical Engineering from Engineer School, Nantes University - FRANCE. I am quick at learning, hard working, results oriented and really creative. I think the combination of knowledges in both programming and Image with training and experience will enable me to make contribution to your laboratory. The following is what I am familiar with * C, C++, Fortran, Pascal and Visual-Basic * Sun OpenWindows, MS-Windows 3.1, X-WINDOW, GKS, ... * Unix SunOs, AIX, MS-Dos 6.0 * 3D Image, ray-tracing, ... * MS-Word, FrameMaker, Ventura-Publisher My resume is enclosed for your reference. Thank you for considering my qualifications for any potential position. Please call or e-mail me if I can provide any additional information. Sincerely, Nicholas MENOUX =============================================================================== NICHOLAS MENOUX Current address: 10, rue Michelet F35700 RENNES FRANCE Phone: (33)99368508 Fax: (33)99286957 E-mail: nmenoux@univ-rennes1.fr Date of birth: 01/25/69 Nationality: French Marital Status: Single Languages spoken: English (TOEFL 567), German, French EDUCATIONAL BACKGROUND ====================== 1990-1992 Three-year course in IRESTE (University of Nantes - Graduate School of Electrical Engineering and Computer Science) MS CS/EE : Diploma obtained in June 1992 1988-1989 Two-year preparation school in depth math & physics courses (intensive preparation for the competitive entrance examination giving access to advanced national schools of engineering) 1987 Baccalaureat C (French equivalent to the Higher Leaving Certificate, math and physics, with scientific orientation) ABILITIES ========= * Sense of Creativity * Resourcefulness and Adaptation Operating Systems: DOS, MS Windows, Unix, Aix, ... Graphic Interfaces: Windows, X-Window, GKS, Phigs, Openview, Sunview, ... Languages: C, C++, Pascal, SQL, Visual Basic, ... MicroP: 68000, 80x86, 6502, ... PROFESSIONAL BACKGROUND ======================= 1993 Project of Genealogy research programm with MS-Windows and Borland C++ : (graphic interface, easy to use, powerful tree drawing, ...) Contacts with french firm to commercialize it in France. 1992 IBM France (Montpellier). Six-month industrial training period as a local area network administrator in the Advanced Techniques Group. I was responsible for 20 Xstations, 6 PS2 and 3 RS/6000 workstations under AIX 3.2 and TCP/IP protocols. I designed an Xwindow module in order to facilitate LAN administration. Moreover, I made a close study of external connections on Internet with X.25 protocols (IP encapsulated). 1992 Real-time application in VxWorks environment. I set a real-time speed control up in a distributed architecture with a Sun Sparc and two 68030 VME cards. The Sun workstation was used to design the speed graph (Sunview) and both VME cards to control the motor. 1992 I carried out a graphic program to assist researchers in spectrum analysis. (Atomic and Molecular Physics Department - University of Rennes - France) 1991 Two-month industrial training period with the S2HF research laboratory in Nantes. This laboratory works on Hyper-frequency for radar measurements. I made an easy and interactive interface to visualize 2D & 3D hyper-frequency images. 1991 Communication project selected by the Telesystems Institute of Paris. I presented my project in May 1991 in M.I.T and Boston Communication School. 1990 Industrial training period with La Telephonie Centrale (French Telephone Company which marketed Numeris(ISDN) telephone). I designed and carried out a local area network to facilitate interdepartment communication inside the company. I used Dbase III+ with DBcom option module and LAN servers. 1988-1989 I designed my own 1200 bps server at home on Apple //c. It was based on the modem card of the well-known french terminal : MINITEL. 1987 One-month training period with GRAVI Production (French company specialized in Image Synthesis and 3D animation). I made a program on Apple //c to preview 3D wire frames and a serial link to the main graphic server. 1984 I designed a video-game in 6502 machine code on Oric Atmos. It was selected by LORICIELS french video-game editor. 1983 I designed my first video-game "CANADA" on ORIC-1. It was commercialized by MICROLOGIC, a french video-game editor. MISCELLANEOUS ============= * Numerous travels all around the World (USA, Russia, European and Eastern countries, ...) * Participate in different school newspapers * Arabic Calligraphy. * Black & White photographs, Drawing * Squash From owner-immunology@net.bio.net Mon Mar 07 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!gatech!news-feed-1.peachnet.edu!umn.edu!msus1.msus.edu!vax1.mankato.msus.edu!vengeance Newsgroups: bionet.immunology Subject: Omaha Project Message-ID: <1994Mar8.084239.2351@vax1.mankato.msus.edu> From: vengeance@vax1.mankato.msus.edu Date: 8 Mar 94 08:42:39 -0500 Organization: Mankato State University Lines: 9 I am trying to build a list of names and E-Mail addresses of people in the Omaha Nebraska area for a school related project. If you live in Omaha or go to school there or know someone that does and will be around for three months or more, please reply via E-Mail to Vengeance@vax1.mankato.msus.edu. Thank you very much! Ryan Krueger From owner-immunology@net.bio.net Mon Mar 07 22:00:00 1994 Path: biosci!infomed.sld.cu!monoclon From: monoclon@infomed.sld.cu (Ctro Inmunologia Molecular) Newsgroups: bionet.immunology Subject: AABOUT THE CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA Date: 8 Mar 1994 05:14:32 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 215 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9403071924.AA04636@infomed.sld.cu> NNTP-Posting-Host: net.bio.net WHAT IS CIM THE CENTER OF MOLECULAR IMMUNOLOGY (CIM) is a research - production institution with more than 60 scientists and engineers, devoted to basic research and product development in the fields of monoclonal antibodies and cancer vaccines. THE WORLD SCIENCE CONTEXT Molecular immunology is just emerging and opening enormous new possibilities of applications. This is because it is the uncoding of an information system. Somewhere in the sixties, molecular genetics started to discover the organization and functioning of the information pieces stored in DNA, and the relationships between this information and the biological experiences of the species. Nowadays a second information system (the immune system) is being well understood and this system, beyond the biological experience of the species, stores the individual experience coded on a repertoire of protein receptors. When one realizes that the potential diversity of only the antibody repertoire is calculated to be near 10X30 it is clear that we have barely started to take the first steps inside the possibilities of such an eficient molecule invention machinery. Molecular Immunology is a field of interphases. It is a mixture of Immunology, Molecular Biology, Cell Culture, Fermentation, Pharmacology, Clinical expertise and so on. Success depends not only on how in depth one can go in any of these disciplines, but also on how to mix knowledge across disciplines borders. That is what CIM is doing. THE NATIONAL CONTEXT Biotechnology was identified as a national priority by the cuban government early in the eighiies . Big investments have been performed to create new scientific institutions, scale up facilities, nation wide laboratory networks and commercial enterprises.This emerging Biotechnology industry profited the enormous investment previously made in education, scientific research and public health. The most well known investment of the nascent biotechnology industry is what is called The West Havana Scientific Pole: it is a zone of the town where more than 20 scientific centers and production facilhies are located near each other. One of them is The Center of Molecular Immunology. CIM is located near The Finlay Institute for vaccine production, The Center of Genetic Engineering and Biotechnology, Center of Medical and Surgical Research, The Center of Immunoassay, The Faculty of Pharmaceutical Sciences, the Faculty of Medicine, among others. CIM has promoted the creation of monoclonal antibody laboratories inside the Faculties of Medicine in 13 out of 14 provinces of the country. This is a nation wide network which increases research capahilities and also guarantees practical uses of MAb based products. HISTORY OF CIM. The Center of Molecular Immunology is a new ins~tution, that gathers an experienced scientific staff in the field of monoclonal antibodies. The senior staff of CIM is a group of scientists which started working in the seventies in the experimental research division of the National Institute of Oncology and Radiobiology ()INOR) . At that time the control of cell proliferation, immunology of lyrnphomas and screening of new immunomodulators were the main fields of research . They also camed out research on horrnone receptors and growth factors in cancer. World on monoclonal antibodies (MAbs started in 1981. One of the first INOR MAbs, an anti T lymphocyte (CD6 antibody) was used in vivo for the treatment of lymphoma akeady in 1984. In the second half of the eighties research on monoclonal antibodies becarne one of the Institute's priorities. A new clinical trial using anti CD3 antibody as immunosuppressor in organ transplantation started in 1987. The product was registered in Cuba in 1989. At that time, space and equipment limitations prevented further scaling-up MAb production. Therefore, in 1990, CIM was decided to be created gathering the majority of the previous INOR experimental research staff and also hiring other scientists and engineers with experience in Fermentation, Scale up production and Quality Control Programs. Building of new facilities started in 1991. THE STAFF. The permanent staff of CIM consists 62 scientists and engineers, directly involved in research and production. Most of them have received training in Europe, mainly in Sweden, France, Germany, U.K., and Holland. The 29 scientists that conform the core group of this staff have been working together for more than 10 years. There has been an effort to keep the staff highly heterogeneous in professional background. Medical Doctors..6 Physics......4 Biologists......1 Chemists.....6 Biochemists..20 Veterinary Doctors..2 Engineers...........9 Managing positions are currently occupied by: Director: Dr. Agustin Lage, Ph.D. Vice-Director of Research & Development: Dr. Rolando Perez, Ph.D. Vice-Director of Production: Eng. Joaqu!n Vill n, Ph.D. Quality Assurance Dept.: Dr. Teresita Rodriguez, Ph.D. THE FACILITIES The new facility of CIM is a 12 000 sqm building. The ground floor was built according to the principle of box into box. The core units are the cell culture, fermentation and purification areas. They are surrounded by a clean hall which cornmunicates through air locks with peripheric laboratories for research diagnostic production and quality control department. The second floor is for technical services and administration. A system for filtered air at 9 diferent pressure levels guarantees class 10 000 and class 100 000 in 560 sqm areas respectively. Cleanest operations are performed in class 100 stations inside class 10 000 rooms. The building is supplied by 5 water loops of different qualities from normal sanitary water up to "water for injection". Gas, waste treatmentt and "cleaning in place" services are also provided. Up stream production flows through three paralell ways: Mouse ascites, hollow fiber bioreactors and stirred tank fermenters. Down strearn purification consises of concentrative filtration followed by different chromatographic steps (i.e.ion exchange, affinity) A computer network connects all units for collection and processing of production data, and scientific information. The facility allows to produce Monoclonal Antibodies up to Kilogram levels and to handle more than 100 cell strains. It has been built according to current GMP guidelines for manufacturing products intended for human use. CURRENT WORK FIELD. There are three levels of activity according to development stage of products and results: . mature product research y Developing products y Basic research. Mature products are those with enough evaluation to be given to other Institutions. They currently are: y a panel of monoclonal antibodies for immunophenotyping of leukocyte subpopulations. y a panel of monoclonal antibodies for tumor diagnosis. y a panel of monoclonal antibodies for research y ELISA systems for carcinoembryonic antigen determination in serum and Hb detection in stool. y purified gangliosides y a monoclonal antibody for intravenous application as an irnmunosuppresor, in the prevention and treatment of rejection crisis in organ transplantation. Several scientific and medical instilutions participate in research projects for further evaluation of usefulness of these products. Participation of new institutions is wellcome. Developing products are in turn at different levels of preclinical and clinical evaluation and they include: y Two new monoclonal antibodies for the treatment of Iymphomas and epidermoid carcinomas. y Three new radioactive monoclonal antibodies for tumor imaging. y new tumor marker Elisa systems. y new monoclonal antibodies for immunohistochemistry. Basic research proJects concentrate in the idea of breaking tolerance to self antigens expressed in malignant tumors. Gangliosides and Epidermal Growth Factor receptor are the two main models. New antiidiotypic antibodies are also being investigated. LOOKING FOR PARTNERS. CIM actively promotes international cooperation. Science today requires not only intelligent production of new knowledge but also intelligent "recombination" of the existing one. As in gene evolution, "recombination" is a source of new traits that is as important as new information. Several different cooperation modalities can be considered: y joint research projects. y cooperation in the generation of a new hybridoma y cooperation in scaling up the production of an existing hybridoma y joint development of a new MAb based product y research cooperation in some of the CIM products y joint chnical trials The reader of this brochure has now enough information to asses if his Institution has areas of overlapping interests and if a cooperation meeting is worth to be promoted. HOW TO CONTACT US: Center of Molecular immunology. PO.BOX: 16040. Havana 11600, CUBA. Fax 53-7-33 35 09 53-7-335049 E.Mail: monoclon@infomed.sld.cu With US the best way is electronic mail!!!!!! From owner-immunology@net.bio.net Tue Mar 08 22:00:00 1994 Path: biosci!WRAIR-EMH1.ARMY.MIL!dexper From: dexper@WRAIR-EMH1.ARMY.MIL Newsgroups: bionet.immunology Subject: source of cyclosporin A Date: 9 Mar 1994 00:16:10 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 9 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403090016.QAA28318@net.bio.net> NNTP-Posting-Host: net.bio.net Cyclosporin A is manufactured by Sandoz Pharma LTD in Basle, Switzerland and is distributed in the U.S. by Sandoz Pharmaceuticals Corp, East Hanover, NJ 07936. When I wanted to use cyclosporine in research, I had to get it through a hospital that is connected to our institute, since the amount I needed was too small for them to sell to me. Jack Komisar dexper@wrair-emh-1.army.mil From owner-immunology@net.bio.net Tue Mar 08 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!torn!camtwh.eric.on.ca!camtwh.eric.on.ca!not-for-mail From: gorska@camtwh.eric.on.ca (Barbara Gorska) Newsgroups: bionet.immunology Subject: Amputation and arthritis Date: 9 Mar 1994 16:01:52 -0500 Organization: Eye Research Inst. of Canada Lines: 13 Distribution: world Message-ID: <2lldg0$j33@camtwh.eric.on.ca> NNTP-Posting-Host: camtwh.eric.on.ca Hi! I am not sure if this is the right place to post such a query, but I have exhausted all other sources. I am a hospital-based health sciences librarian and I was asked by one of our doctors if there is a connection between amputation of the upper limb and osteoarthritis in the other upper limb. Can anybody give me any suggestions how to approach this problem? Thank you Barbara Gorska gorska@camtwh.eric.on.ca From owner-immunology@net.bio.net Tue Mar 08 22:00:00 1994 Path: biosci!daresbury!bioftp.unibas.ch!rc1.vub.ac.be!dec5dbm.ulb.ac.be!tsornas From: tsornas@dbmdec5.ulb.ac.be (Thierry Sornasse) Newsgroups: bionet.immunology Subject: Re: Opinions on whether TH1 and TH2 cell types originate from TH0 Date: 9 Mar 1994 16:37:41 GMT Organization: Brussels Free Universities VUB/ULB Lines: 58 Sender: tsornas@dec5 (Thierry Sornasse) Distribution: world Message-ID: <2lku0l$f7c@rc1.vub.ac.be> References: <2lindk$1uv@tamsun.tamu.edu> NNTP-Posting-Host: dbmdec5.ulb.ac.be Hi Immunonetters, The discrimination between Th1 and Th2 phenotypes was established from data about T cell clones derived from mice. With this background, it is possible to characterize individual cells. Although, if you look in vivo, the image you will get is quite more confuse. Moreover, the studies made in human suggest strongly that the simple scheme of Th1/Th2 is rather difficult to apply. On the other hand, if you focus your attention on global response and not on single cells, I think that it is possible to characterize either Th1 like response or Th2 like response. In each case the cytokines and the effectors implied in hte response will be different, altho!ugh with some overlapping. I think that in the scope of therapy, the global evaluation of Th1/Th2 balance should lead to better results than the fine description of individual clones. I think that is one of the reason why immunologist look only to specific cytokines like IL4,IL10,IL2 and IFNg. The detection of these cytokines is sufficient to predict with a good confidence the type of response studied. About the hypothesis that Th1 and Th2 are the result of the differentiation of Th0, I am convince that is the best way to describe the regulation of the immune response with the present background. This hypothesis fit perfectly in vitro experiments (patterns of cytokines secreted by T cells which have been activated once or twice). The paper of the team of A. O'Garra about the role of macrophages and dendritic cells in the differentiation of Th1 clones from naive T cells confirms this hypothesis. In fact, you need both DC and Mac to get a optimal Th1 differentiation. DC activate naive T cells but do not trigger the differentiation of Th1, while Mac do not activate naive T cells but trigger the differentiation of Th1 by secreting IL12. In other words, DC would allow the activation of Th0 and Mac would allow the differentiation of activated Th0 to Th1. In vivo, the situation seems to be more complicated. If you consider an adult human, his immune system is not naive. Thus, there could be some memory T cells that are already shifted to Th1 or to Th2. In conclusion, I could say that the relevance of the Th1/Th2 discrimination depends on the scale at which you study the immune system: the model fits well to a global scale but the at the clonal scale the model is practically useless. Best regards ///////////////////////////////////////////////////////////////////////// / / T H I E R R Y S O R N A S S E / / Laboratoire de Physiologie Animale / / Universite Libre de Bruxelles / Free University of Brussels / Rue des Chevaux, 67. 1640 Rhode-St-Genese / B E L G I U M / / Phone: 32.2.6509850 Fax: 32.2.6509840 / tsornas@dbmdec5.ulb.ac.be / / //////////////////////////////////////\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ From owner-immunology@net.bio.net Tue Mar 08 22:00:00 1994 Newsgroups: bionet.immunology Path: biosci!agate!ihnp4.ucsd.edu!sdd.hp.com!nigel.msen.com!math.fu-berlin.de!zib-berlin.de!uni-paderborn.de!urmel.informatik.rwth-aachen.de!newsserver.rrzn.uni-hannover.de!newsserver.rrzn.uni-hannover.de!hkatz From: hkatz@nucmed.med.nyu.edu (Henry Katz) Subject: HSV meningitis Message-ID: Sender: news@newsserver.rrzn.uni-hannover.de (News Service) Organization: RRZN Date: Wed, 9 Mar 1994 06:47:22 GMT Lines: 22 Could anyone give me references and or groups conducting inquiries into the following topic: What are the factors responsible for the retrograde propagation in normal non-immunocompromised individuals of HSV after an anterograde topical herpetic lesion outbreak leading to meningitis? If any interest I can refer you to workers currently treating such a patient. TIA, hek _____________________________________________________________________________ |Henry Katz | | |ISCS, Inc | email: | |1.212.685.3057 | work: hkatz@lehman.com | | Currently on contract at: | play: hkatz@nucmed.med.nyu.edu | |Lehman Brothers | voice: 1.212.464.7319 | |388 Greenwich St | fax: 1.212.464.3118 | |NY NY 10013 | pager: 1.917.899.1420 | ------------------------------------------------------------------------------ From owner-immunology@net.bio.net Tue Mar 08 22:00:00 1994 Path: biosci!daresbury!not-for-mail From: Graham Pawelec Newsgroups: bionet.immunology Subject: EUCAMBIS Date: 9 Mar 1994 14:23:55 -0000 Lines: 66 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2lkm5r$bnu@mserv1.dl.ac.uk> Original-To: "bionet discussion group imm. & ageing" , immuno@dl.ac.uk With this posting, allow me to introduce a new initiative of the European Union (EU), scheduled to start at the beginning of April 1994, called EUCAMBIS (= EU Concerted Action on the Molecular Biology of Immunosenescence), of which I am the coordinator. This is one of a large series of EU concerted actions covering many areas of biomedical science. The concept of the concerted action is simply that it should be a mechanism to facilitate the collaboration of different groups (in Europe) on particular areas of research. In our case, we are concentrating on immunosenescence of the T cell, employing an interdisciplinary approach to define genetic events correlating with altered immune functioning in aged individuals. This research network will bring together molecular biologists, gerontologists and immunologists to study T cell function in healthy aged people, patients with progeroid syndromes and other genetic diseases known or suspected to manifest accelerated senescence phenotypes, and to compare these with events occuring in vitro in a long- term culture model of T cell ageing. The expression of growth arrest- specific genes, known tumor-suppressor genes and cell cycle control genes will be investigated in these materials and correlated to cellular immunological function of the cells. We will attempt to isolate novel genes that are upregulated during ageing and to identify senescence- inducing genes or those that contribute actively to the senescent phenotype. Molecular data will be correlated with alterations of function assesssed by cytokine gene transcription and protein secretion, development of cytotoxicity or suppressor capacity. The relationship, if any, between senescence programs and those involved in the special type of T cell growth arrest designated "anergy" will be investigated. Obviously, such a project covers a multitude of sins, and we expect to have to play it by ear. I am particularly keen to hear from non-European scientists interested in any of these areas (but also of course, European workers as well) to start a dialogue on these aspects of immunogerontological research. In an attempt to broaden potential collaboration from its purely European (and small!) base, I am particularly interested to hear from any non-European scientists who might like to work with us for a year or so in Tuebingen (small medieval south-west German University city near Lake Constance, the Alps and the Black Forrest) on this project. We would have to obtain dedicated funding for these persons, but clearly I would assist in the preparation of any applications for funding fellowships, stipendia etc. Please feel free to contact me on the any of the above points, or to request further information on any particular component. With best regards to all readers of this notice, Graham ############################################################ # # # Graham Pawelec, # # Second Department of Internal Medicine, # # University of Tuebingen Medical School, # # D-72076 Tuebingen, Germany; # # # # Coordinator, European Union Concerted # # Action on the Molecular Biology of # # Immunosenescence, EUCAMBIS. # # # # e-mail INTERNET: pawelec@mailserv.zdv.uni-tuebingen.de # # # # Phone: +49-7071-29-2805 # # # # FAX: +49-7071-29-4464 # # # ############################################################ From owner-immunology@net.bio.net Wed Mar 09 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!europa.eng.gtefsd.com!news.umbc.edu!haven.umd.edu!purdue!lerc.nasa.gov!magnus.acs.ohio-state.edu!lritter From: lritter@magnus.acs.ohio-state.edu (Linda M Ritter) Newsgroups: bionet.immunology Subject: Thank you for the help Date: 10 Mar 1994 16:46:07 GMT Organization: The Ohio State University Lines: 10 Sender: lritter@magnus.acs.ohio-state.edu Message-ID: <2lnisf$ul@charm.magnus.acs.ohio-state.edu> NNTP-Posting-Host: top.magnus.acs.ohio-state.edu Summary: Growing U937 cells Thank you to all who responded to my request for help growing U937 cells in spinner flasks. My cells are a variant that do not attach to a substrate but grow in suspension. I appreciated the responses and solutions offered. This was my first post to this newsgroup and was pleased by the warm response. Thanks again. Linda From owner-immunology@net.bio.net Wed Mar 09 22:00:00 1994 Path: biosci!infomed.sld.cu!monoclon From: monoclon@infomed.sld.cu (Ctro Inmunologia Molecular) Newsgroups: bionet.immunology Subject: IIMMUNOTHERAPIC MEETING HAVANA-CUBA Date: 10 Mar 1994 09:13:16 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 473 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9403092203.AA22332@infomed.sld.cu> NNTP-Posting-Host: net.bio.net IMMUNOTHERAPY IN THE NINETIES: The impact of molecular immunology in the treatment of cancer and autoimmune diseases International Workshop Center of Molecular Immunology Havana City, Cuba May 16-20, 1994 SPONSORED BY: PAN-AMERICAN HEALTH ORGANIZATION T H I R D A N N O U N C E M E N T I.- MEETING COMPOSITION In the previous 2nd Announcement, the organizing committe advanced some ideas about the reasons for this meeting, the topics to be discussed and the fundamental questions to be addressed. These ideas were well received by the scientific community active in the field. Up to now, the following scientists have expressed intention to participate: List of Invited Speakers NAME COUNTRY POSITION 1. Prof. Peter Biberfeld Sweden Head, Lab of Immunopathology, Karolinska Institute. 2. Prof. G. Dighiero France Chief, Service of Immunohematology and Immunopathology. Pasteur Institute. 3. Dr. James Larrick USA Scientific Director, Palo Alto Institute for Molecular Medicine. 4. Prof. Jesper Zeuthen Denmark Head, Department of Tumor Cell Biology, The Fibiger Institute, Danish Cancer Center. 5. Prof. Philip USA Head, Clinical Livingston Immunology Service, Memorial Sloan Kettering Cancer Center. 6. Prof. Willian J. Harris UK President and Chief Harris Scientific Officer, Scotgen Biopharmaceuticals. 7. Prof. Sherie L. USA Chairman and Profesor, Morrison Dept. of Microbiology and Genetics UCLA, University of California. 8. Dr. Dan Holmberg Sweden Chief, Dept. for Cell and Molecular Biology. University of Umea. 9. Dr. Tadashi Tai Japan Chief of Dept. of Tumor Immunology. Tokyo Metropolitan Institute of Medical Science. 10. Prof. Donald Marcus USA Chief, Section on Rheumatic Diseases. Baylor College of Medicine. 11. Dr. Jacques France Director of Research Portoukalian Inserm. Institut National de nti et de la Recherche Modicale 12. Prof. Carlos Spain Director, Centro de Biologia Molecular Martinez Universidad Autonoma de Madrid. 13. Dr. Andrew UK Senior Scientist Griffiths Medical Research Council (MRC), Cambridge Centre for Protein Engineering. 14. Dr. Heinz Kohler USA Medical Doctor, Ph.D. University of Kentuchy. 15. Dr. Jacques Aubry France Senior Scientist. University of Nantes. Institut National de la Santi et de la Recherche Midicale. 16. Dra. Cecilia Chile Head of the Immunology Sepulveda Unit. University of Chile. 17. Dra. Christiane Argentina Head, Dpt. Medicine Dosne National Academy of Medicine. Buenos Aires. 18. Dr. Agustin Lage Cuba Director. Center of Molecular Immunology 19. Dr. Rolando Perez Cuba Research Director Center of Molecular Immunology. 20. Dr. Luis Fernandez Cuba Head of Immunochemistry Lab. Center of Molecular Immunology. 21. Dr. Jorge Gavilondo Cuba Head of the Diagnostic Division. Center of Genetic Engineering and Biotechnology. 22. Dr. Carlos Garcia Cuba Head of the Clinical Immunology Lab. National Institute of Oncology and Radiobiology. 23. Dr. Gustavo Sierra Cuba Vice-President. Finlay Institute. Representations of scientific journals are also being invited. The meeting will gather around 50 people, in a context adequate for intensive discussion. II.- MEETING ORGANIZATION In the previous 2nd announcement, the organizers advanced several questions around which discussions could be focussed. These were: Is it practically possible to re-program the adult immune system for recognizing tumors as "nonself"? Which molecules could be the best targets for an autoimmune rejection of tumors? Can growth factors and growth factor receptors be presented as autoantigens? Which ways are available today to modify presentation of tumor-associated antigens? Is it possible to induce a mature response (high affinity antibodies produced by conventional B cells in germinal centers) to T-independent self-antigens? Can the conventional B cell repertoire be induced to react to the antigens of the B-CD5+ repertoire? What experimental strategies can be designed in order to identify meaningful cross-reactive idiotopes on human V-regions and to evaluate the clinical significance of their measurement? Can idiotypic connectivity be artificially manipulated (increased or decreased) in the adults central immune system? Which would be the predicted outcomes of such an intervention? Is it possible to design a laboratory test for the measurement of idiotypic connectivity in adult humans? Is it possible to design a laboratory test for measuring the reduction of diversity that take place in the B-CD5+ repertoire during aging? Can this reduction of diversity be related to the increase in the incidence of tumors and autoimmune disease with aging? What is the predictable impact of antibody engineering technology on the therapeutic efficacy of monoclonal antibodies? What is the role of B-1a (CD5+), B-1b (sister) and B-conventional lymphocyte subpopulations in the immune response to tumor antigens? Which procedures can be designed today in order to induce (or suppress) specifically selected idiotypes in the adults repertoire? These questions are still non-operational. It is, they can not be directly translated into experiments to answer them. This is surely a very difficult task. In fact, the formulation of the critical questions which are both meaningful and experimentally accesible is the core of scientific creativity. Immunology is full of non-operational concepts. For items such as network antigen, self-related antigen, regulatory idiotope, suppresor clone, idiotypic conectivity, and many others there is not a clear-cut experiment to define it. The therapeutic manipulation of the repertoire of immune receptors in order to reprogram the system to reject new antigens (cancer) or to accept other ones (autoimmune diseases, organ transplantation), is a very appealing idea. If the meeting is able: to define each concept in operational (experimentally accessible) terms, to decompose each question into questions susceptible to be addressed through an experiment, then meeting would have contributed to the advancement of "Immunotherapy in the Nineties". The organization of the meeting has been conceived to create possibilities for this intellectual enterprise. The following is a preliminary Program. Any suggestion of participants about this preliminary Program will be highly appreciated and taken into account. PRELIMINARY PROGRAM MONDAY 16 Morning 9:00 . Wellcome speech Dr. Miguel Marquez Head of WHO/PAHO Office in Havana. . Acreditation of participants. . Overview of facilities of the Center of Molecular Immunology. 10:30 . Coffee Break 11:00 . Opening Conference. Fundamental obstacles for a rational thera- peutic manipulation of the repertoire of immune receptors. Dr. Agustmn Lage (Cuba) 12:00 . Discussion 1:00 . Lunch identification of human diseases MONDAY 16 Afternoon Chairman: Dr. Cristina Mateo 2:00 . Enhancement of Antibody Function. Dr. Sherie L. Morrison (USA) 2:30 . Discussion 3:00 . Production of Humanised Monoclonal Antibodies for in vivo imaging and therapy. Dr. W.J. Harris (UK) 3:30 . General Discussion 4:00 . Coffee Break 4:30 . Monoclonal Antibodies from combinatorial immunoglobulin libraries. Prospects and current limitations. Dr. Donald Marcus (USA) 5:00 . Discussion 5:30 . Antibody engineering. New perspectives. Dr. Andrew Griffiths (UK) 6:00 . Discussion TUESDAY 17 Morning Chairman: Dr. Amparo Macmas 9:00 . Natural Antibodies. Dr. G. Dighiero (France) ven clone selection, affinity 9:30 . Discussion 10:00 . Coffee Break 10:30 . Natural Antibodies, effective B-Cell repertoire develop- ment and autoimmune pathogenesis. Dr. Dan Holmberg (Sweden) 11:00 . Discussion 11:30 . Current status of idiotypic vaccines for cancer therapy. Heinz Kohler (USA) 12:00 . Discussion 1:00 . Lunch internal world seems to TUESDAY 17 Afternoon Chairman: Dr. Amparo Macias 2:00 . MRL/lpr A5 a model for developing and testing models in immunotherapy. Dr. Carlos Martinez (Spain) 2:30 . Discussion 3:00 . The EGF-system as a target of cancer immunotherapy. Dr. Agustin Lage (Cuba) 3:30 . Discussion 4:00 . Coffee Break 4:30 . Recurrent Idiotypes and idiotype-induced T Cell suppresion concepts: their impact in cancer vaccine design. Dr. Rolando Pirez (Cuba) 5:00 . General Discussion WEDNESDAY 18 Morning Chairman: Dr. Oscar Valiente 9:00 . Immunotherapy of human tumor-associated gangliosides: a pilot study of the EORTC melanoma group. Dr. Jacques Portoukalian (France) 9:30 . Discussion carrier sequences 10:00 . Coffee Break 10:30 . Towards v-gene repertoire of antiganglioside anti bodies. Dr. Jacques Aubry (France) 11:00 . Discussion 11:30 . Ganglioside-KLH conjugate vaccines plus a potent immunological adyuvant, results in prolonged IgM and IgG antibody responses in patients with melanoma. Dr. Philip Livingston (USA) 12:00 . Discussion session about vaccine design will 1:00 . Lunch WEDNESDAY 18 Afternoon Chairman: Dr. Oscar Valiente 2:00 . Characterization of ganglioside expression in human melanoma cells: Immunological and biochemical analysis. Dr. Tadashi Tai (Japan) 2:30 . Discussion 3:00 . Monosialoganglioside, GM3 and derivatives as targets for cancer immunotherapy. Dr. Luis E. Fernandez (Cuba) 3:30 . Discussion 4:00 . Coffee Break 4:30 . Computer-assisted modeling of ganglioside antigens: energetic mapping of self epitopes. Dr. Juan D. Garrido (Cuba) 5:00 . Discussion 5:30 . Selection of carriers, adjuvants and potentiators for new vaccines. Dr. Gustavo Sierra (Cuba) 6:00 . General Discussion THURSDAY 19 Morning Chairman: Dr. Ana M. Vazquez (Cuba) 9:00 . T-Cell receptor variable gene usage in tumor infil- trating lymphocytes in malignant melanoma. Dr. Jesper Zeuthen (Denmark) 9:30 . Discussion 10:00 . Coffee Break 10:30 . Anti B-7 therapeutics. The therapeutic use of recent knowledge about the CD28-B7 pathway. Dr. James W. Larrick (USA) 11:00 . Discussion 11:30 . The dual role of the immune system in tumor development. Dr. Christiane D. Pasqualini (Argentina) 12:00 . Discussion 1:00 . Lunch THURSDAY 19 Afternoon Chairman: Dr. Ana M. Vazquez 2:00 . New anti IL-6 and immunoprotocol for treatment of AIDS lymphoma. A model for anti-growth factor immunotherapy. Dr. Peter Biberfeld (Sweden) 2:30 . Discussion 3:00 . The treatment of lymphoma with anti-CD6 monoclonal antibodies. Dr. Carlos Garcma (Cuba) 3:30 . Discussion 4:00 . Coffee Break 4:30 . Expression of Antibody Fragments in E. Coli. Dr. Jorge Gavilondo (Cuba) 5:00 . General Discussion FRIDAY 20 Morning ""Buffer" Session: topics to be The morning session is announced. FRIDAY 20 Afternoon 2:00 . Visit to biotechnology facilities in the west zone of Havana. 4:00 . Concluding session. From owner-immunology@net.bio.net Thu Mar 10 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!europa.eng.gtefsd.com!emory!nigel.msen.com!math.fu-berlin.de!zib-berlin.de!tertius.in-berlin.de!novell-del-valle.RZ-Berlin.MPG.DE!del_valle Newsgroups: bionet.immunology Subject: Human IgA Message-ID: From: del_valle@MPIMG-Berlin-Dahlem.MPG.DE (Jesus del Valle) Date: Fri, 11 Mar 1994 13:44:24 UNDEFINED Organization: MPI fuer molekulare Genetik, Berlin, Germany Nntp-Posting-Host: novell-del-valle.rz-berlin.mpg.de Nntp-Posting-User: nntp_client X-Newsreader: Trumpet for Windows [Version 1.0 Rev B] Lines: 9 Hi. I am currently studying the IgA protease of the pathogenic bacterium Neisseria meningitidis. It is known to cleave only human IgA1 and primates IgA therefore I am interested in the following questions: Since they only differ in 20 of the approx. 330 aa comprising the alpha chain, is there a functional difference between both human IgAs (IgA1 and IgA2)?. Do cells expressing them are somehow different or react to different interleukins or anything else?. Do other primates or animals have also two or more IgAs?. Any comments or literature references will be appreciated. Thanks a lot. Jesus del Valle From owner-immunology@net.bio.net Thu Mar 10 22:00:00 1994 Path: biosci!VTVM1.CC.VT.EDU!VERPHELD From: VERPHELD@VTVM1.CC.VT.EDU (Daniela verthelyi) Newsgroups: bionet.immunology Subject: Help Date: 11 Mar 1994 17:31:55 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 9 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403111731.JAA01155@net.bio.net> NNTP-Posting-Host: net.bio.net Hi, I need to get Beta2-Glycoprotein I, a glycoprotein that has been associated with increased binding of anticardiolipin antibodies. I havce been able to induce these antibodies in normal mice, and I would like to to look at their bi nding in the presence of this glycoprotein. Does anybody know of a source for this product? Thank you Daniela Verthelyi VA-MD Veterinary College Virginia Tech (703)231-7757 Verpheld@VTVM1 From owner-immunology@net.bio.net Fri Mar 11 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!pipex!zaphod.crihan.fr!univ-lyon1.fr!ghost.dsi.unimi.it!batcomputer!cornell!uw-beaver!netnews.nwnet.net!news.u.washington.edu!michaelr From: michaelr@u.washington.edu (Michael Robertson) Newsgroups: bionet.immunology Subject: Re: Human IgA Date: 11 Mar 1994 19:50:20 GMT Organization: University of Washington, Seattle Lines: 20 Message-ID: <2lqi1s$k6g@news.u.washington.edu> References: NNTP-Posting-Host: stein.u.washington.edu In article , Jesus del Valle wrote: >Hi. I am currently studying the IgA protease of the pathogenic bacterium >Neisseria meningitidis. It is known to cleave only human IgA1 and primates >IgA therefore I am interested in the following questions: Since they only >differ in 20 of the approx. 330 aa comprising the alpha chain, is there a >functional difference between both human IgAs (IgA1 and IgA2)?. Do cells >expressing them are somehow different or react to different interleukins or >anything else?. Do other primates or animals have also two or more IgAs?. >Any comments or literature references will be appreciated. Thanks a lot. >Jesus del Valle Does anyone know if US researchers can obtain reagents throught the MRC AIDS Reagent Project and/or the ANRS Programme Reactifs SIDA? If so, what is the cost, etc. Thanks. Reply by e-mail From owner-immunology@net.bio.net Fri Mar 11 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!EU.net!howland.reston.ans.net!pipex!zaphod.crihan.fr!univ-lyon1.fr!ghost.dsi.unimi.it!batcomputer!cornell!uw-beaver!netnews.nwnet.net!news.u.washington.edu!michaelr From: michaelr@u.washington.edu (Michael Robertson) Newsgroups: bionet.immunology Subject: AIDS Reagents Date: 11 Mar 1994 19:56:56 GMT Organization: University of Washington, Seattle Lines: 8 Message-ID: <2lqie8$kaf@news.u.washington.edu> NNTP-Posting-Host: stein.u.washington.edu Does anyone know if US researchers can obtain reagents throught the MRC AIDS Reagent Project and/or the ANRS Programme Reactifs SIDA? If so, what is the cost, etc. Thanks. Reply by e-mail From owner-immunology@net.bio.net Sat Mar 12 22:00:00 1994 Path: biosci!daresbury!doc.ic.ac.uk!agate!usenet.ins.cwru.edu!magnus.acs.ohio-state.edu!gchacko From: gchacko@magnus.acs.ohio-state.edu (George W Chacko) Newsgroups: bionet.molbio.methds-reagnts,bionet.immunology Subject: Diluted ECL Reagent ? Followup-To: bionet.molbio.methds-reagnts Date: 12 Mar 1994 23:59:37 GMT Organization: The Ohio State University Lines: 9 Message-ID: <2ltl19$avh@charm.magnus.acs.ohio-state.edu> NNTP-Posting-Host: bottom.magnus.acs.ohio-state.edu Xref: biosci bionet.molbio.methds-reagnts:12370 bionet.immunology:1149 Has anyone tried to dilute Amersham's ECL reagent? The kind of signal I get usually requires 3-10 secs exposure and it occurred to me that if I could dilute the reagent in TBS-T or something I wouldn't use it up as fast. George From owner-immunology@net.bio.net Sun Mar 13 22:00:00 1994 Path: biosci!daresbury!not-for-mail From: Graham Pawelec Newsgroups: bionet.immunology Subject: T cell senescence project "EUCAMBIS" Date: 14 Mar 1994 17:29:12 -0000 Lines: 66 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2m26t8$9sv@mserv1.dl.ac.uk> Original-To: "bionet discussion group imm. & ageing" , immuno@dl.ac.uk With this posting, allow me to introduce a new initiative of the European Union (EU), scheduled to start at the beginning of April 1994, called EUCAMBIS (= EU Concerted Action on the Molecular Biology of Immunosenescence), of which I am the coordinator. This is one of a large series of EU concerted actions covering many areas of biomedical science. The concept of the concerted action is simply that it should be a mechanism to facilitate the collaboration of different groups (in Europe) on particular areas of research. In our case, we are concentrating on immunosenescence of the T cell, employing an interdisciplinary approach to define genetic events correlating with altered immune functioning in aged individuals. This research network will bring together molecular biologists, gerontologists and immunologists to study T cell function in healthy aged people, patients with progeroid syndromes and other genetic diseases known or suspected to manifest accelerated senescence phenotypes, and to compare these with events occuring in vitro in a long- term culture model of T cell ageing. The expression of growth arrest- specific genes, known tumor-suppressor genes and cell cycle control genes will be investigated in these materials and correlated to cellular immunological function of the cells. We will attempt to isolate novel genes that are upregulated during ageing and to identify senescence- inducing genes or those that contribute actively to the senescent phenotype. Molecular data will be correlated with alterations of function assesssed by cytokine gene transcription and protein secretion, development of cytotoxicity or suppressor capacity. The relationship, if any, between senescence programs and those involved in the special type of T cell growth arrest designated "anergy" will be investigated. Obviously, such a project covers a multitude of sins, and we expect to have to play it by ear. I am particularly keen to hear from non-European scientists interested in any of these areas (but also of course, European workers as well) to start a dialogue on these aspects of immunogerontological research. In an attempt to broaden potential collaboration from its purely European (and small!) base, I am particularly interested to hear from any non-European scientists who might like to work with us for a year or so in Tuebingen (small medieval south-west German University city near Lake Constance, the Alps and the Black Forrest) on this project. We would have to obtain dedicated funding for these persons, but clearly I would assist in the preparation of any applications for funding fellowships, stipendia etc. Please feel free to contact me on the any of the above points, or to request further information on any particular component. With best regards to all readers of this notice, Graham ############################################################ # # # Graham Pawelec, # # Second Department of Internal Medicine, # # University of Tuebingen Medical School, # # D-72076 Tuebingen, Germany; # # # # Coordinator, European Union Concerted # # Action on the Molecular Biology of # # Immunosenescence, EUCAMBIS. # # # # e-mail INTERNET: pawelec@mailserv.zdv.uni-tuebingen.de # # # # Phone: +49-7071-29-2805 # # # # FAX: +49-7071-29-4464 # # # ############################################################ From owner-immunology@net.bio.net Mon Mar 14 22:00:00 1994 Path: biosci!infomed.sld.cu!monoclon From: monoclon@infomed.sld.cu (Ctro Inmunologia Molecular) Newsgroups: bionet.immunology Subject: EUCAMBIS!!! Date: 15 Mar 1994 05:17:29 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 16 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9403141807.AA23655@infomed.sld.cu> NNTP-Posting-Host: net.bio.net We have known about EUCAMBIS through Bionet discussion group. The idea of a concerted action seems very attractive. We work at the Center of Molecular Immunology in Havana, CUBA; a research facility actively working on monoclonal antibodies and cancer vaccines. One of the teams has been studying natural autoantibodies against peptide growth factors. Main interest has been autoantibody relationships with malignant tumors. However, a screening on healthy population is going on (for setting up good controls) and these measurements can provide information about aging also. Would a subject like this be interesting for EUCAMBIS? Are there other on going projects about this? Which members of Bionet discussion group are involved in autoantibody research? We would like to identify people active in the field in order to exchange more specific information. You can also contact us by fax. (537-335049) From owner-immunology@net.bio.net Mon Mar 14 22:00:00 1994 Path: biosci!agate!howland.reston.ans.net!EU.net!Germany.EU.net!netmbx.de!zib-berlin.de!news.belwue.de!news.uni-ulm.de!news From: CCC_GAME@rzmain.rz.uni-ulm.de (Gamel Anton) Newsgroups: bionet.immunology Subject: Q: IF 2nd ABs Mono- or Polyklonal? Date: 15 Mar 1994 11:27:49 GMT Organization: University of Ulm, Germany Lines: 35 Distribution: world Message-ID: <2m463l$pe0@wega.rz.uni-ulm.de> NNTP-Posting-Host: main01.rz.uni-ulm.de X-News-Reader: VMS NEWS v1.25 High all! With indirect immunofluorescence double labelling experiments I have made good experiences using first ABs from different species and goat polyklonals as 2nd ABs (FITC and Cy3 conjugated) Now I have to set up a double labelling with two monoklonals from mouse differing only in the isotype: IgG1 contra IgG2b. There are lots of conjugated polyklonals that discriminate IgG1 and IgG2b, what about the cross reactions? The experiment should show the two antigens in one cell. There are some monoklonal 2nd ABs (only one red) available. I suppose they are much more specific but expensive and all from rat. Could there occur other cross reactions e.g. Rat@IgG2b binding to a RatIgG2b@MouseIgG1?? What system should I use monoclonal or polyclonal and are there other tricks to get good results in this case? Every comment is appreciated! Many thanks Best greetings Anton J. Gamel If possible please reply directly to +-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-+ : : : : Anton J. Gamel : o o : : ------------------------ : V : : Look, a Vet on VAX : (,,) : : : -""-- : +-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-+ From owner-immunology@net.bio.net Mon Mar 14 22:00:00 1994 Path: biosci!agate!howland.reston.ans.net!pipex!warwick!not-for-mail From: lsrbd@csv.warwick.ac.uk (Chris Hodgson) Newsgroups: bionet.immunology Subject: Re: Opinions on whether TH1 and TH2 cell types originate from TH0 Date: 15 Mar 1994 17:42:00 -0000 Organization: University of Warwick, Coventry, UK Lines: 73 Message-ID: <2m4s18$b3l@crocus.csv.warwick.ac.uk> References: <2lindk$1uv@tamsun.tamu.edu> NNTP-Posting-Host: crocus-fddi.csv.warwick.ac.uk Mime-Version: 1.0 Content-Type: text/plain; charset=US-ASCII Content-Transfer-Encoding: 7bit Dear Immunonetters, I feel that this discussion warrants some clarification and further opinion. I am in agreement with the recent article postees as regards the presence of TH1 and TH2 cells during differing responses. My personal interest lies within sensitization to chemical allergens, some of which can be classified aas respiratory or contact dermatitis agents. However the immune response at the TH cell level is not absolute to one or the other committed cytokine-based cell types, rather both specific TH1 & TH2 cells are formed during rounds of clonal expansion to an antigen (be this microbial, oncogenically derived or allergen). The balance between specific TH1 and TH2 cells is altered according to the antigen(s), the cell types and millieu in which they are presented and is further likely to be mediated by a parallel clonal selection of B-cells with lymph nodes local to the inflammatory site [i.e. a region from which antigen is derived by APC, and which attracts specific T and B lymphocytes from the circulating networks) In essence I am saying that one or the other type of TH cell may predominate at the antigenic site - this effect will be more markedly apparent during a true amanestic memory response where memory cells rapidly commit to the beginnings of inflammation. Good evidence exists for the role of TH1 specific cytokines in mediating delayed type hypersensitivity, and also for TH2 cytokines in recruiting the cells types (eosinophils in particular) associated with late-phase reaction in asthma. I would be interested to know if anyone is aware of what happens to a TH1 or TH2 cell once infection has been curbed / erradicated. Do they fractionate into populations as follows : 1) TH1 and/or TH2 cells, short lived and poised for blast formation 2) TH1 and/or TH2 cells, long lived memory cells (CD45 isoforms ?) 3) TH0 cell state - Can a TH1 or TH2 cell return to this and retain a memory phenotype thus having the potential to become either TH1 or TH2-like on future encounters with the same of similar antigen ? It does not seem beyond credibility that all three of the above types of population may result following "recovery". I think it likely that in recurrent asthmatics and eczema sufferers that frequent exposure to allergens never gives the TH2-like cells responding any opportunity to diminish at reactive inflammatory sites - this might futher be maintained by B-cell IgE production which is just ticking over and longer term antigen presentation both at previously damaged tissue regions and within regional lymph nodes. I certainly feel that the TH1 / TH2 phenotype are the extremes of TH cell development and are only readily observable during an ongoing immune response. I begin to view them more as a product of short-term immunoevolution within mammals, recruiting different effector cells and inducing appropriate killing mechanisms (e.g DTH is essential for virally infected cell erradication). Finally, in what has been a long post (my apologies), I do not see any problems in the manner in which we classify TH1/TH2 like cells based on their cytokine-production potential. From tissue biopsies most workers approach the analysis by mRNA in-situ hybridisation, in vivo cultures can demsonstrate secretion patterns of clones or mixed cells. I encourage and welcome further discussion from all of the newsgroup readers on this thread - TH1 and TH2 cells are pivotol to the effector phase of immune respones and are here to stay. Chris Hodgson -- Chris Hodgson \Where all roads lead to mystery University of Warwick \Serendipity will be found Coventry, U.K. \---94-- +44 203 523523 Ext. 2568 \lsrbd@csv.warwick.ac.uk From owner-immunology@net.bio.net Wed Mar 16 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!eunet.no!EU.net!howland.reston.ans.net!vixen.cso.uiuc.edu!miklaszs1.life.uiuc.edu!smiklasz From: smiklasz@ux1.cso.uiuc.edu (Steven Miklasz) Newsgroups: bionet.immunology Subject: Monoclonal Antibody Date: Thu, 17 Mar 1994 18:41:37 Organization: Immunological Resource Center Lines: 9 Message-ID: NNTP-Posting-Host: miklaszs1.life.uiuc.edu Keywords: Anti- RNA Polymerase X-Newsreader: Trumpet for Windows [Version 1.0 Rev A] I would like to know if anyone has information regarding monoclonal antibodies made against rna polymerase. I would be greatful if you could email me information about its availability. Thanks in advance, Steven Miklasz Immunological Resource Center School of Life Sciences University of Illinois at Urbana-Champaign From owner-immunology@net.bio.net Wed Mar 16 22:00:00 1994 Path: biosci!CS.Arizona.EDU!math.arizona.edu!news.Arizona.EDU!hamblin.math.byu.edu!sol.ctr.columbia.edu!emory!europa.eng.gtefsd.com!library.ucla.edu!agate!doc.ic.ac.uk!lyra.csx.cam.ac.uk!pavo.csi.cam.ac.uk!pipex!zaphod.crihan.fr!jussieu.fr!univ-lyon1.fr!swidir.switch.ch!cisun2000.unil.ch!isrec-sun1.unil.ch!rhartman From: rhartman@isrec-sun1.unil.ch (Reto Hartmann) Newsgroups: bionet.immunology Subject: Help! c-Yes antibody Date: 17 Mar 1994 10:04:54 GMT Organization: University of Lausanne CH (Switzerland) Lines: 10 Message-ID: <2m9a06$1mn@cisun2000.unil.ch> NNTP-Posting-Host: isrec-sun1.unil.ch X-Newsreader: TIN [version 1.1 PL8] Hi does anyone out there have or know who has an antibody to p62 c-Yes? Any information would be helpful. thanks Reto -- Reto Hartmann Ludwig Institute for Camcer Research, Lausanne rhartman@isrec-sun1.unil.ch From owner-immunology@net.bio.net Wed Mar 16 22:00:00 1994 Path: biosci!CCMAIL.LLU.EDU!dLee From: dLee@CCMAIL.LLU.EDU ("dLee") Newsgroups: bionet.immunology Subject: Re: Intracellular self/not-self discrimination Date: 17 Mar 1994 22:42:52 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 66 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9402177639.AA763944588@ccmail.llu.edu> NNTP-Posting-Host: net.bio.net It's been two weeks since Dr. Forsdyke posted this message, and unfortunately, I haven't seen any comments on it (although I do occassionally miss some of the posted items). So, since we've been discussing the item here, I'll throw out a few of our objections. Mind you, they are not objections to the possibility of intracellular self/not-self discrimination, but arguments against the need for it. Forsdyke writes: > Since the final T cell repertoire reflects the processes of > negative and positive selection, every additional functional MHC > gene would increase the number of potential anti-self T cells which > would have to be deleted (negative selection). This would decrease > the range of foreign proteins to which the surviving positively > selected cells could respond. Fitness would be impaired. Individuals > which lost excess MHC loci through mutation, would then have a > selective advantage ... I agree with his interpretation of the effect of increased MHC expression on negative selection, but he seems to have ignored the effect on positive selection. Since the vast majority of T cells are neither positively nor negatively selected (99%), the newly-selected thymocytes (positive or negative) would be primarily from the pool of cells which previously had been non-selected. Increased MHC-peptide combinations in thymic development would be more effective in increasing the number of positively selected thymocytes from the large non-selected pool than increasing the number of negatively selected thymocytes from the small positively-selected pool. With this in mind, the reason for a limitted set of MHC might be to maximize antigenic responsiveness while keeping the potential for *peripheral* development of autoreactivity (as a product of rare TCR mutation) at a minimum. > In the absence of a mechanism for distinguishing intracellularly > self peptides or proteins from foreign (e.g. virally-derived) > peptides or proteins, cells would have to display all MHC-bound > peptides. Hedrick (1992) has noted that "It is hard to understand > how peptides derived from foreign antigens can compete with the tide > of self peptides...", and has suggested that "Perhaps there is a > mechanism that could help to sort peptides into those originating > from self and those originating from foreign peptides". To begin with, this is much more of a problem for Class I, presenting intracellular antigens (self-antigens being produced on a constant basis), than Class II, presenting phagocytized extracellular antigens. However, even this might not be a problem, if one considers the differential production of foreign antigens versus self antigens during something like viral infection or bacterial phagocytosis. In both situations, I would expect a majority of the MHC (Class I and II, respectively) to be presenting foreign antigenic peptides. Even in situations of low antigen concentrations, it has been estimated that only 50-300 TCR must be engaged with MHC-peptide to trigger a full T cell response. Considering 10^4-10^5 TCR per T cell and 10^5-10^7 MHC per APC, all of the above arguements might be moot, since very few of the MHC even need to have foreign antigen peptides to effect a T cell response. ********************************************************************* Dean Lee * We dance 'round in a ring * Dept of Micro and Mol Genetics * and suppose, * Loma Linda University * But the secret sits in the middle * dLee@ccmail.llu.edu * and knows. R. Frost * ********************************************************************* From owner-immunology@net.bio.net Thu Mar 17 22:00:00 1994 Path: biosci!BCRSSU.AGR.CA!RAMPITSCH From: RAMPITSCH@BCRSSU.AGR.CA Newsgroups: bionet.immunology Subject: mono vs polyclonals; cross-reactions Date: 17 Mar 1994 20:44:17 -0000 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 43 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <01HA30FVOJN6002PLH@GW.AGR.CA> >High all! >With indirect immunofluorescence double labelling experiments >I have made good experiences using first ABs from different >species and goat polyklonals as 2nd ABs (FITC and Cy3 conjugated) >Now I have to set up a double labelling with two monoklonals >from mouse differing only in the isotype: IgG1 contra IgG2b. >There are lots of conjugated polyklonals that discriminate >IgG1 and IgG2b, what about the cross reactions? >The experiment should show the two antigens in one cell. >There are some monoklonal 2nd ABs (only one red) available. >I suppose they are much more specific but expensive and all >from rat. Could there occur other cross reactions e.g. >Rat@IgG2b binding to a RatIgG2b@MouseIgG1?? >What system should I use monoclonal or polyclonal and are there >other tricks to get good results in this case? >Every comment is appreciated! Hi: If your assay allows it, why don't you conjugate your Ab with flourochrome (or whatever); you'll lose sensitivity and its a bit of a hassle, but you'll have no cross reactions. Otherwise I think I'd go for the monoclonals, although I have had good luck with some batches of polyclonals in similar situations, however, my system (DAS ELISA) could tolerate cross reaction - I dind't mind a slight background. Try conjugation. cheers, -------------------------------------------------------------------------------- Chris Rampitsch | RAMPITSCH@BCRSSU.AGR.CA Dept. Plant Science, Univ. of BC | Phone (604) 494-7711 Vancouver, British Columbia | Fax (604) 494-0755 Canada V6T 2A2 _/\_ ---------------------------------- __\ /__ ------------------------------------ "Most people don't act stupid;... \__ __/ ..it's the real thing." A.E.Neuman ______________________________________||________________________________________ From owner-immunology@net.bio.net Thu Mar 17 22:00:00 1994 Path: biosci!internet!biosci!not-for-mail From: kristoff (David Kristofferson) Newsgroups: bionet.immunology Subject: IMPORTANT BIOSCI INFORMATION Date: 18 Mar 1994 02:00:20 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 244 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403181000.CAA10480@net.bio.net> NNTP-Posting-Host: net.bio.net Three important items follow: BIOSCI archive searching by e-mail, the BIOSCI FAQ, and the BIOSCI User Address Directory form. If you have not yet listed yourself in our e-mail address directory, please take a few minutes to complete and return the form below. If your address information has changed since you listed yourself, please send us an updated form. Sincerely, Dave Kristofferson BIOSCI/bionet Manager kristoff@net.bio.net **** SEARCHING BIOSCI ARCHIVES WITH WAISMAIL **** E-mail users can search the BIOSCI archives by using our waismail e-mail server. For instructions send the message help to waismail@net.bio.net. Leave the Subject: line blank. Other methods of searching the archives via WAIS and gopher are described in the BIOSCI FAQ. **** BIOSCI FREQUENTLY ASKED QUESTIONS (FAQ) SHEET **** New users of BIOSCI/bionet may want to read the "Frequently Asked Questions" or "FAQ" sheet for BIOSCI. The FAQ provides details on how to participate in these forums and is available for anonymous FTP from net.bio.net [134.172.2.69] in pub/BIOSCI/doc/biosci.FAQ or for retrieval by gopher to net.bio.net, port 70. It may also be requested by sending e-mail to biosci-help@net.bio.net (use plain English for your request). The FAQ is also posted on the first of each month to the newsgroup BIONEWS/bionet.announce immediately following the posting of the BIOSCI information sheet. **** BIOSCI USER ADDRESS DIRECTORY **** Please take this opportunity to add your name and address information to the BIOSCI User Address Database if you have not already done so. Below is the address form that we would like each reader of the BIOSCI/bionet newsgroups to complete and return if you would like to be listed in our database. The database serves as a directory that enables biologists, who are currently using (or even just reading) the BIOSCI newsgroups, to look up e-mail addresses and other information about our users. The address database is reindexed nightly for WAIS and waismail access (waismail is our WAIS e-mail server, more below) and will also be available for access via other gopher sites if they wish to permit it. The raw unindexed data is available for FTP from net.bio.net and is atomized sufficiently to allow import into your local RDBMS should you so desire. Please carefully follow the instructions for completing the form below and return it to either of the following two addresses (whichever is more convenient for you). Thanks in advance for taking the time to complete and return the form. Addresses for returning forms Location Network ----------------------------- -------- ------- biovote@net.bio.net U.S.A. Internet/BITNET biovote@daresbury.ac.uk U.K. JANET MAKING SURE THAT YOUR INFORMATION IS CURRENT This notice will be mailed bimonthly to each newsgroup. You should check our WAIS source or waismail e-mail server from time-to-time to see if your address information is still up-to-date. Send the message help to waismail@net.bio.net for instructions on using waismail. Leave the Subject: line in your message blank. Using Gopher to complete the form --------------------------------- If you don't want to use a text editor, you can also use Dan Jacobson's gopher site to fill out the address database form as follows. Otherwise skip this section on gopher and proceed to the instructions for filling out the form below. > To add yourself to the database just point your > gopher client at merlot.gdb.org and select the following: > > --> 15. Searching For Biologists/ > > --> 9. E-mail Addresses of Biosci-Bionet Users/ > > --> 1. Add (or Correct) Your Address to the BIOSCI User Address > Data.. > > > And fill out the form. or Rob Harper's gopher site in Europe as follows: > Europeans can point their gopher client at gopher.csc.fi and add their > information to the database. All entries will be mailed directly to > Dave for incorporation in a wais source. > > The path to the questionare is as follows. > > ---> 10. Finnish EMBnet BioBox/ > > ---> 8. FAQ Files/ > > FAQ Files > > 1. EMBnet: Information. > 2. EMBnet: Internet resources guide. > 3. A Biologist's Guide to Internet Resources/ > 4. All FAQs (Frequently Asked Questions) Searches and Archives/ > --->5. Bionauts Address Database (questionaire) IMPORTANT INSTRUCTIONS - PLEASE READ CAREFULLY Please enter all responses after the : on each line, leaving one (1) blank space after the : (i.e., before the start of your text). Please do NOT extend your responses past the end of each line (80 characters) or alter any of the field identifiers such as "first name: ". Several lines are provided at the end of the form for comments, but, please adhere to the line length restriction. On the date: line, please enter the date in the DD-MM-YY format, e.g., 05-05-93 for 5 May 1993. This line will tell others when the information was last updated. Please be sure to include the 0's for single digit days or months, e.g., 05-05-93, not 5-5-93. Note that the "e-mail network: " line below is for specifying, e.g., "Internet," "BITNET," "EARN," "JANET," or whatever other network that your computer may be on. If you are uncertain about any field, please feel free to leave it blank, but please DO NOT DELETE the field identifier from the form! In the first field below, "New information or Update ...", please enter "N" if this is the first time that you have registered in the directory or "U" if you are correcting a listing that you sent to us previously. The comment: lines may be used for anything that you like but PLEASE DO NOT DELETE THEM FROM THE FORM OR ALTER THEM. One suggested use is to list the names of the newsgroups in which you participate. Please use the MAILING LIST name (see below - the latest version of the list can be requested from biosci@net.bio.net) instead of the USENET name even if you don't participate by e-mail. WAIS might get confused by the periods in the USENET names. This allows one to retrieve via WAIS or waismail the list of participants in a particular group. For example: comment: ARABIDOPSIS PLANT-BIOLOGY BIONEWS On the comment: lines use these names below ---- NOT the USENET names below MAILING LIST NAME USENET Newsgroup Name ----------------- --------------------- ACEDB-SOFT bionet.software.acedb AGEING bionet.molbio.ageing AGROFORESTRY bionet.agroforestry ARABIDOPSIS bionet.genome.arabidopsis BIOFORUM bionet.general BIO-INFORMATION-THEORY bionet.info-theory BIONAUTS bionet.users.addresses BIONEWS bionet.announce BIO-JOURNALS bionet.journals.contents BIO-MATRIX bionet.molbio.bio-matrix BIO-SOFTWARE bionet.software CHROMOSOMES bionet.genome.chromosomes COMPUTATIONAL-BIOLOGY bionet.biology.computational DROSOPHILA bionet.drosophila EMBL-DATABANK bionet.molbio.embldatabank EMPLOYMENT bionet.jobs GDB bionet.molbio.gdb GENBANK-BB bionet.molbio.genbank GENETIC-LINKAGE bionet.molbio.gene-linkage HIV-MOLECULAR-BIOLOGY bionet.molbio.hiv HUMAN-GENOME-PROGRAM bionet.molbio.genome-program IMMUNOLOGY bionet.immunology INFO-GCG bionet.software.gcg JOURNAL-NOTES bionet.journals.note METHODS-AND-REAGENTS bionet.molbio.methds-reagnts MOLECULAR-EVOLUTION bionet.molbio.evolution NEUROSCIENCE bionet.neuroscience N2-FIXATION bionet.biology.n2-fixation PHOTOSYNTHESIS bionet.photosynthesis PLANT-BIOLOGY bionet.plants POPULATION-BIOLOGY bionet.population-bio PROTEIN-ANALYSIS bionet.molbio.proteins PROTEIN-CRYSTALLOGRAPHY bionet.xtallography RAPD bionet.molbio.rapd SCIENCE-RESOURCES bionet.sci-resources TROPICAL-BIOLOGY bionet.biology.tropical VIROLOGY bionet.virology WOMEN-IN-BIOLOGY bionet.women-in-bio YEAST bionet.molbio.yeast Listing newsgroups on the comment: line is optional, of course. Thanks again for your cooperation! --------------- please cut here and return portion below --------------- New information or Update to old record (enter N or U): date (DD-MM-YY): first name: middle initial: family name: job title: e-mail address: e-mail network: phone number: FAX number: institution: address1: address2: address3: city: state/province: country: postal code: research interest: research interest: comment: comment: comment: comment: comment: From owner-immunology@net.bio.net Thu Mar 17 22:00:00 1994 Path: biosci!UVVM.UVIC.CA!LSDA From: LSDA@UVVM.UVIC.CA (Larry Anthony) Newsgroups: bionet.immunology Subject: IFN and IL-4 assays Date: 18 Mar 1994 09:48:33 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 6 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <199403181748.JAA29511@net.bio.net> NNTP-Posting-Host: net.bio.net Greetings fellow Immunonetters! I, too, am in the market for peoples recommendations for a commercia l source of cytokine ELISA kits. I am particularly interested in IFN-g, IL-2, IL-4, IL-10 and IL-12. Any thoughts? Larry LSDA@UVVM.UVic.Ca From owner-immunology@net.bio.net Thu Mar 17 22:00:00 1994 Path: biosci!daresbury!not-for-mail From: mbstg@seqnet.dl.ac.uk Newsgroups: bionet.immunology Subject: IFN-g Abs Date: 18 Mar 1994 10:05:58 -0000 Lines: 19 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2mbue6$h5t@mserv1.dl.ac.uk> Original-To: immuno@dl.ac.uk Dear Netcolleagues, I'm urgently seeking to set up a direct (not an effector) assay for murine IFN-g, and I wonder if anyone could recommend a commercial source for an ELISA kit. We also want to look at in vivo neutralisation of IFN-g. All the Abs I have seen to date such as R4-6A2 are supposed to require growth in nu.nu mice in order to get sufficient concentration for in vivo neutralistaion, and this is not practical for us. So any advice on expereinces with in vivo neutralisation using culture s/n concentrates, or again commercial suppliers of purified high neutralising activity Abs to IFN-g would be very welcome thanks Jeremy Sternberg Dept of Zoology Univ of Aberdeen, Scotland e-mail:j.sternberg@abdn.ac.uk or mbstg@dl.ac.uk From owner-immunology@net.bio.net Thu Mar 17 22:00:00 1994 Path: biosci!CCMAIL.LLU.EDU!dLee From: dLee@CCMAIL.LLU.EDU ("dLee") Newsgroups: bionet.immunology Subject: Re: mono vs polyclonals; cross-reactions Date: 18 Mar 1994 09:46:43 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 37 Sender: daemon@net.bio.net Distribution: bionet Message-ID: <9402187640.AA764013276@ccmail.llu.edu> NNTP-Posting-Host: net.bio.net >There are lots of conjugated polyklonals that discriminate >IgG1 and IgG2b, what about the cross reactions? Polyclonals made to discriminate between these two must be adsorbed or absorbed against the other subclasses in order to be specific, since any immunization with one IgG class will generate antibodies to both class-specific and subclass-specific epitopes. If absorbed on a column, the resulting polyclonal should be ok, but if adsorbed directly, the immune complexes will be left in the Ab solution and may create problems. >There are some monoklonal 2nd ABs (only one red) available. >I suppose they are much more specific but expensive and all >from rat. Could there occur other cross reactions e.g. >Rat@IgG2b binding to a RatIgG2b@MouseIgG1?? Since rat and mouse are genetically close, and immunizations rarely induce autoantibodies, a rat mAb against mouse IgG2b will have been selected (during the initial immunization/antibody response) for epitopes which rat does not have in common with the mouse. The cross-reaction you describe above would be very unlikely. >What system should I use monoclonal or polyclonal and are there >other tricks to get good results in this case? Extended incubations in the cold at low antibody concentrations has been, in our experience, the general rule for the best combination of sensitivity and specificity. ********************************************************************* Dean Lee * We dance 'round in a ring * Dept of Micro and Mol Genetics * and suppose, * Loma Linda University * But the secret sits in the middle * dLee@ccmail.llu.edu * and knows. R. Frost * ********************************************************************* From owner-immunology@net.bio.net Fri Mar 18 22:00:00 1994 Path: biosci!daresbury!trane.uninett.no!sunic!pipex!howland.reston.ans.net!usenet.ins.cwru.edu!magnus.acs.ohio-state.edu!ptiwari From: ptiwari@magnus.acs.ohio-state.edu (Pratima Tiwari) Newsgroups: bionet.immunology,bionet.virology,bionet.molbio.hiv Subject: Information Requested Date: 19 Mar 1994 14:37:57 GMT Organization: The Ohio State University Lines: 7 Message-ID: <2mf2o5$c75@charm.magnus.acs.ohio-state.edu> NNTP-Posting-Host: beauty.magnus.acs.ohio-state.edu Xref: biosci bionet.immunology:1162 bionet.virology:426 bionet.molbio.hiv:332 Please reply to my email which will be easier for me access. Thanks Pratima PS if It is wrong network or crosslisted, sorry. I am asking info for first time. Email... ptiwari@magnus.acs.ohio-state.edu From owner-immunology@net.bio.net Fri Mar 18 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!usenet.ins.cwru.edu!magnus.acs.ohio-state.edu!ptiwari From: ptiwari@magnus.acs.ohio-state.edu (Pratima Tiwari) Newsgroups: bionet.immunology,bionet.virology,bionet.molbio.hiv Subject: Information requested Date: 19 Mar 1994 14:50:00 GMT Organization: The Ohio State University Lines: 14 Message-ID: <2mf3eo$c88@charm.magnus.acs.ohio-state.edu> NNTP-Posting-Host: beauty.magnus.acs.ohio-state.edu Xref: biosci bionet.immunology:1163 bionet.virology:427 bionet.molbio.hiv:333 Can anybody suggest/ write on Hepatitis B and its treatment? An acquiantance got infected with that during leg fracture operation oversees and has been told 'no cure'. I am trying to gather more information and if we have treatment facilities in United states. Any suggestion will be appreciated. Please reply to my email which will be easier for me access. Thanks Pratima PS if It is wrong network or crosslisted, sorry. I am asking info for first time. Email... ptiwari@magnus.acs.ohio-state.edu From owner-immunology@net.bio.net Sat Mar 19 22:00:00 1994 Path: biosci!daresbury!not-for-mail From: mkuiper@crc.ac.uk (Mr. M. Kuiper) Newsgroups: bionet.immunology Subject: Anergy & Memory Date: 20 Mar 1994 12:34:12 -0000 Lines: 14 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2mhfs4$3tm@mserv1.dl.ac.uk> Original-To: immuno@dl.ac.uk Hello immunonetters, Has anybody out there an idea about the question if anergized T-cells generate memory cells? The concept of anergy vs activation is quite difficult for me, since I think that anergized and activated T-cells against the same antigen might exist side by side. To me this seems to be a very inefficient and possibly dangerous for the organism, depending on which of both populations is dominant. The question whether anergized T-cells generate memory cells is central to me in this process, because anergy could then be equally impor- tant to activation in a 2nd response to an antigen. Marcel Kuiper. mkuiper@uk.ac.crc.hgmp or rchz103@uk.ac.kcl.cc.bay From owner-immunology@net.bio.net Sun Mar 20 22:00:00 1994 Path: biosci!bcm!cs.utexas.edu!howland.reston.ans.net!pipex!sunic!trane.uninett.no!daresbury!not-for-mail From: Newsgroups: bionet.immunology Subject: Re: EUCAMBIS Date: 21 Mar 1994 08:58:52 -0000 Lines: 21 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2mjnkc$m7a@mserv1.dl.ac.uk> X-Mts: smtp X-Char-Esc: 29 X-Charset: ASCII Original-To: immuno@dl.ac.uk If there is interest from the countries associated with EU (in this case of the Czech Republic) drop me message with more details about (how to apply) details at one of the addresses bellow. Greetings, ////////////////////////////////////////////////// / / / Milan Jira, M.D., Ph.D. / / 3rd Medical School, Charles University / / RuskNS 87, 100 00 Praha 10 / / Czech Republic / / Phone: +42-2-739451, ext. 439, 440 / / Fax: +42-2-67311812 / / E-mail: Milan.Jira@lf3.cuni.cz / / jira@maclc.ruk.cuni.cz / / ulimj@earn.cvut.cz / / ULIMJ@CSPUNI12 / / / ////////////////////////////////////////////////// From owner-immunology@net.bio.net Mon Mar 21 22:00:00 1994 Path: biosci!daresbury!not-for-mail From: Kurt Schaudt Newsgroups: bionet.immunology Subject: Re: Anergy & Memory Date: 22 Mar 1994 14:58:16 -0000 Lines: 51 Sender: daemon@mserv1.dl.ac.uk Distribution: bionet Message-ID: <2mn128$j67@mserv1.dl.ac.uk> Original-To: Immunology discussion group Marcel Kuiper wrote: >Hello immunonetters, > >Has anybody out there an idea about the question if anergized T-cells generate >memory cells? > >The concept of anergy vs activation is quite difficult for me, since I >think that anergized and activated T-cells against the same antigen might >exist side by side. To me this seems to be a very inefficient and possibly >dangerous for the organism, depending on which of both populations is >dominant. The question whether anergized T-cells generate memory cells is >central to me in this process, because anergy could then be equally impor- >tant to activation in a 2nd response to an antigen. > >Marcel Kuiper. mkuiper@uk.ac.crc.hgmp or rchz103@uk.ac.kcl.cc.bay Induction of anergy must be seen as one step in a sequential process (of the immune response); it is not induced at the start of an immune response. When an immune response is started, its efficacy will depend on the time needed for producing a sufficient amount of competent t cells (starting from theoretically one cell!), meanwhile the target cells still will continue growing. This race can only be won if cells of the immune system will grow much faster than the target cells, so they must go through maximal stimulation (supplied by suitable interleukines allowing the specific t cells to grow exponentially). However, using this kind of maximal stimulation is most dangerous for the organism and only reasonable if there exist effectual steps for extinguishing this now needless growth when the fight is won (and the cells still are growing exponentially). This extinguishing can be (and is) reliably performed by apoptosis. But it would be a pity to kill all the labourious produced t cells. Better, to keep a small percentage alive but resting - for the next time! And that is done by anergy. In our experience, in experiments inducing anergy there is always a considerable percentage of cells lost by apoptosis. It seems that in the mechanism of extinguishing the immune response a procedure is comprised that ENSURES (seems to be not accidentally) a certain percentage of cells to escape from apoptosis by getting anergic. Obviously in this extinguishing process the cytotoxic t cells must be involved, there may be any mechanism enabling idle (because they find no target cell) CTL's to stimulate other t cells (antigen specific) without appropriate costimulus and so inducing apoptosis or anergy within them. So far it is unclear how the decision apoptosis/anergy is made (I would like to hear suggestions!). Kurt Schaudt Medical School of Tuebingen Germany kschaudt@mailserv.zdv.uni-tuebingen.de From owner-immunology@net.bio.net Mon Mar 21 22:00:00 1994 Path: biosci!VTVM1.CC.VT.EDU!CVMBMD From: CVMBMD@VTVM1.CC.VT.EDU ("D. Wise") Newsgroups: bionet.immunology Subject: need help culturing CTLL cells Date: 21 Mar 1994 18:17:10 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lin